WO2010123838A2 - Nouveaux dérivés amide et amidine et leurs utilisations - Google Patents

Nouveaux dérivés amide et amidine et leurs utilisations Download PDF

Info

Publication number
WO2010123838A2
WO2010123838A2 PCT/US2010/031660 US2010031660W WO2010123838A2 WO 2010123838 A2 WO2010123838 A2 WO 2010123838A2 US 2010031660 W US2010031660 W US 2010031660W WO 2010123838 A2 WO2010123838 A2 WO 2010123838A2
Authority
WO
WIPO (PCT)
Prior art keywords
cyano
amino
adamantane
methyl
carboxamide
Prior art date
Application number
PCT/US2010/031660
Other languages
English (en)
Other versions
WO2010123838A3 (fr
Inventor
Sridhar Peddi
Meena V. Patel
Jeffrey J. Rohde
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to MX2011011082A priority Critical patent/MX2011011082A/es
Priority to CN201080026472.4A priority patent/CN102459158B/zh
Priority to CA2757866A priority patent/CA2757866A1/fr
Priority to JP2012507294A priority patent/JP5848698B2/ja
Publication of WO2010123838A2 publication Critical patent/WO2010123838A2/fr
Publication of WO2010123838A3 publication Critical patent/WO2010123838A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/14—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/16—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C261/00—Derivatives of cyanic acid
    • C07C261/04—Cyanamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/30—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/40—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C327/42—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/44—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing eight carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/93—Spiro compounds
    • C07C2603/95—Spiro compounds containing "not free" spiro atoms
    • C07C2603/96—Spiro compounds containing "not free" spiro atoms containing at least one ring with less than six members
    • C07C2603/97—Spiro compounds containing "not free" spiro atoms containing at least one ring with less than six members containing five-membered rings

Definitions

  • the present invention relates to novel amide, cyanoamidine, thioamide, amidine, hydroxyimideamide, alkoxyimideamide, aryloxyimideamide and related compounds, which are inhibitors of the 11- ⁇ -hydroxysteroid dehydrogenase type 1 (1 l ⁇ -HSDl) enzyme.
  • the present invention further relates to the use of inhibitors of 1 l ⁇ -HSDl enzyme for the treatment of humans in need thereof.
  • Glucocorticoids circulate in the blood in an active form (i.e., Cortisol in humans) and an inactive form (i.e., cortisone in humans).
  • an active form i.e., Cortisol in humans
  • an inactive form i.e., cortisone in humans
  • 1 l ⁇ -HSDl functions primarily as a reductase in vivo and in intact cells. It converts inactive 11- ketoglucocorticoids (i.e., cortisone or dehydrocorticosterone) to active 11- hydroxyglucocorticoids (i.e., Cortisol or corticosterone), and thereby amplifies glucocorticoid action in a tissue-specific manner leading to higher local concentration of Cortisol.
  • inactive 11- ketoglucocorticoids i.e., cortisone or dehydrocorticosterone
  • active 11- hydroxyglucocorticoids i.e.,
  • 1 l ⁇ -HSDl prevents or decreases the tissue specific amplification of glucocorticoid action thus imparting beneficial effects.
  • 1 l ⁇ -HSDl is a low affinity enzyme with K m for cortisone in the micromolar range that prefers NADPH/NADP + (nicotinamide adenine dinucleotide phosphate) as cofactors.
  • 1 l ⁇ -HSDl is widely expressed in various tissues such as liver, bone, brain, lung, adipose, and vascular smooth muscle cells.
  • glucocorticoid-induced acute psychosis exemplifies a more pharmacological induction of this response, and is of major concern to physicians when treating patients with these steroidal agents (Wolkowitz et al., Ann NY Acad Sci., 1032, 191- 194 (2004)). It has been recently shown that 11 ⁇ -HSD 1 mRNA is expressed in human hippocampus, frontal cortex and cerebellum, and that treatment of elderly diabetic individuals with the non-selective 11 ⁇ -HSD 1 and 1 l ⁇ -HSD2 inhibitor carbenoxolone improved verbal fluency and memory (Thekkapat et al, Proc Natl Acad Sci USA, 101, 6743-6749 (2004)).
  • glucocorticoid levels also affects psychopathology, as shown in animal models, it leads to increased anxiety and aggression. Chronic elevation of Cortisol has been also associated with depression in Cushing's disease (McEwen, Metab. Clin. & Exp., 54, 20-23 (2005)).
  • a number of animal and clinical studies have provided evidence for the correlation between increases in glucocorticoid levels and neuropsychiatric disorders such as major depressive disorder, psychotic depression, anxiety, panic disorder, post traumatic stress disorder, and depression in Cushing's syndrome (Budziszewska, Polish J.
  • inhibiting 11 ⁇ -HSD 1 benefits patients suffering from non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, age-related or glucocorticoid-related declines in cognitive function such as those seen in Alzheimer's disease and associated dementias, major depressive disorder, psychotic depression, anxiety, panic disorder, post traumatic stress disorder, depression in Cushing's syndrome, treatment resistant depression, and other diseases and conditions mediated by excessive glucocorticoid action.
  • One embodiment is directed to a compound of formula (I)
  • L is -(CH 2 V, -(CR 38 R 3 Vx-(CR 38 R 3 V or -(CR 38 R 39 ) m -X-(CR 38 R 39 ) n -Y-; m is independently at each occurrence 0, 1, or 2; n is independently at each occurrence 0, 1, or 2;
  • R 1 is cycloalkyl or heterocycle
  • R 2 is hydrogen, alkyl, or aryl; or R 1 and R 2 together with the atoms to which they are attached form a heterocycle; or R 2 and R 3 together with the atoms to which they are attached form a heterocycle;
  • R 3 and R 4 are independently hydrogen, alkyl or cycloalkyl; or R 3 and R 4 together with the atom to which they are attached form a cycloalkyl, heterocycle, heteroaryl or aryl;
  • R 5 is hydrogen, alkyl, amino, aryl, cycloalkyl, heteroaryl, or heterocycle provided R 5 is other than amino when L is -(CR 38 R 39 ) m -X-(CR 38 R 39 ) n -Y-; or R4 and R 5 together with the atoms to which they are attached form a cycloalkyl or heterocycle;
  • X is -O-, -S-, -S(O)-, -S(O) 2 -, -NR 36 -, or -CR 36 R 37 -;
  • Y is O or NR 40 ;
  • R 36 and R 37 are independently at each occurrence hydrogen or alkyl; or R 36 and R 2 together with the atoms to which they are attached form a heterocycle;
  • R 38 , R 39 and R 40 are independently at each occurrence hydrogen or alkyl
  • W is O, N-CN, N-OR 6 , N-R 6 , or S;
  • R 6 is hydrogen, alkyl or aryl; or a pharmaceutically acceptable salt, ester, amide, N-oxide or prodrug thereof.
  • Another embodiment encompasses the use of the compounds of formula (I) for the treatment of disorders that are mediated by 1 l ⁇ -HSDl enzyme, such as non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, age-related or glucocorticoid-related declines in cognitive function such as those seen in Alzheimer's disease and associated dementias, major depressive disorder, psychotic depression, anxiety, panic disorder, post traumatic stress disorder, depression in Cushing's syndrome, treatment resistant depression, and other diseases and conditions that are mediated by excessive glucocorticoid action.
  • disorders that are mediated by 1 l ⁇ -HSDl enzyme such as non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, age-related or glucocorticoid-related declines in cognitive function such as those seen in Alzheimer's disease and associated dementias, major depressive disorder, psychotic depression, anxiety, panic disorder, post traumatic stress disorder, depression in Cushing's syndrome, treatment resistant depression, and other diseases and conditions
  • Another embodiment is directed to a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) in combination with a pharmaceutically suitable carrier.
  • acetyl means a -C(O)CH 3 group.
  • acyl means an alkyl group appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of acyl include, but are not limited to, acetyl, 1-oxopropyl, 2,2-dimethyl-l-oxopropyl, 1-oxobutyl, and 1- oxopentyl.
  • acyloxy means an acyl group appended to the parent molecular moiety through an oxygen atom.
  • Representative examples of acyloxy include, but are not limited to, acetyloxy, propionyloxy, and isobutyryloxy.
  • alkenyl means a straight or branched chain hydrocarbon containing from 2 to 10 carbons, and preferably 2, 3, 4, 5, or 6 carbons, and containing at least one carbon- carbon double bond.
  • Representative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2- methyl- 1-heptenyl, and 3-decenyl.
  • alkoxy refers to an alkyl group appended to the parent molecular moiety through an oxygen atom.
  • Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy and the like.
  • alkoxyalkoxy means an alkoxy group appended to the parent molecular moiety through another alkoxy group, as defined herein.
  • Representative examples of alkoxyalkoxy include, but are not limited to, te/t-butoxymethoxy, 2-ethoxyethoxy, 2- methoxyethoxy, and methoxymethoxy.
  • alkoxyalkyl means an alkoxy group appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of alkoxyalkyl include, but are not limited to, te/t-butoxymethyl, 2-ethoxy ethyl, 2-methoxy ethyl, and methoxymethy 1.
  • alkoxycarbonyl means an alkoxy group appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of alkoxycarbonyl include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, and tert- butoxy carbonyl .
  • alkoxyimideamide means a >TM ⁇ group.
  • alkoxyimino include, but are not limited to, imino(methoxy)methyl, ethoxy(imino)methyl and tert-butoxy(imino)methyl.
  • alkoxysulfonyl means an alkoxy group appended to the parent molecular moiety through a sulfonyl group, as defined herein.
  • Representative examples of alkoxysulfonyl include, but are not limited to, methoxysulfonyl, ethoxysulfonyl, and propoxy sulfonyl.
  • alkyl means a straight or branched chain hydrocarbon containing from 1 to 6 carbon atoms.
  • Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, ⁇ o-propyl, n-butyl, sec-butyl, ⁇ o-butyl, tert-hvXy ⁇ , n-pentyl, isopentyl, neopentyl, and n-hexyl.
  • the number of carbon atoms in a hydrocarbyl substituent is indicated by the prefix “C x -C y -", wherein x is the minimum and y is the maximum number of carbon atoms in the substituent.
  • C x -C y - refers to an alkyl substituent containing from 1 to 6 carbon atoms.
  • Cs-C ⁇ -cycloalkyl means a saturated hydrocarbyl ring containing from 3 to 6 carbon ring atoms.
  • alkyl-NH-alkyl refers to an alkyl group appended to a second alkyl group, as defined herein through an -NH- group. Said second alkyl group is appended to the parent molecular moiety.
  • alkylcarbonyl refers to an alkyl group appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of alkylcarbonyl include, but are not limited to, acetyl, 1-oxopropyl, 2,2-dimethyl-l-oxopropyl, 1-oxobutyl, and 1-oxopentyl.
  • alkylcycloalkyl means an alkyl group appended to the parent molecular moiety through a cycloalkyl group, as defined herein.
  • Representative examples of alkylcycloalkyl include, but are not limited to, 4-ethylcyclohexyl, 3-methylcyclopentyl, and 2-isopropylcyclopropyl.
  • alkylsulfonyl means an alkyl group appended to the parent molecular moiety through a sulfonyl group, as defined herein.
  • Representative examples of alkylsulfonyl include, but are not limited to, methylsulfonyl and ethylsulfonyl.
  • alkylthio means an alkyl group appended to the parent molecular moiety through a sulfur atom.
  • Representative examples of alkylthio include, but are not limited, methylthio, ethylthio, te/t-butylthio, and hexylthio.
  • amino is -NR 90 R 91 , wherein R 90 and R 91 are each independently hydrogen, alkyl, alkoxy, alkylsulfonyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, arylsulfonyl, alkyl-NH-alkyl, aryl-NH-alkyl, arylalkyl, haloalkyl, aryl-heterocycle, carboxy, carboxyalkyl, carboxycycloalkyl, cycloalkyl, cycloalkyloxy, cycloalkylsulfonyl, heteroaryl, heteroarylalkyl, heteroaryloxyalkyl, heteroaryloxy, heteroarylsulfonyl, heterocycle, heterocycle-NH-alkyl, heterocyclealkyl, heterocycle-heterocycle, heterocycleoxyalkyl, heterocycleoxy, heterocyclesulfonyl, or hydroxyl.
  • alkynyl means a straight or branched chain hydrocarbon group containing from 2 to 10 carbon atoms, and preferably 2, 3, 4, or 5 carbons, and containing at least one carbon-carbon triple bond.
  • Representative examples of alkynyl include, but are not limited to, acetylenyl, 1-propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl.
  • amidine or "imideamide” means a ⁇ group.
  • amido means an amino, alkylamino, or dialkylamino group appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of amido include, but are not limited to, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, and ethylmethylaminocarbonyl.
  • aryl means phenyl, a bicyclic aryl, or a tricyclic aryl.
  • the bicyclic aryl is naphthyl, a phenyl fused to a cycloalkyl, cycloalkenyl, heteroaryl or heterocycle, as defined herein.
  • the bicyclic aryl must be attached to the parent molecular moiety through any available carbon atom contained within the phenyl ring.
  • Representative examples of the bicyclic aryl include, but are not limited to, dihydroindenyl, indenyl, naphthyl, dihydronaphthalenyl, and tetrahydronaphthalenyl.
  • Tricyclic fused ring systems are exemplified by a bicyclic aryl and fused to a cycloalkyl, phenyl, heteroaryl, or heterocycle, as defined herein.
  • the tricyclic aryl is attached to the parent molecular moiety through any carbon atom contained within a phenyl ring.
  • Representative examples of aryl include, but are not limited to, anthracenyl, phenanthrenyl, azulenyl, fluorenyl, indanyl, indenyl, naphthyl, phenyl and tetrahydronaphthyl.
  • aryl groups of this invention may be substituted with 0, 1, 2, 3, 4 or 5 substituents independently selected from alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylsulfonyl, alkynyl, aryl, arylalkoxy, arylcarbonyl, aryloxy, arylsulfonyl, carboxy, carboxyalkyl, cyano, cyanoalkyl, ethylenedioxy, formyl, haloalkoxy, haloalkyl, halogen, heteroaryl, heteroarylalkoxy, heteroarylalkyl, heteroarylcarbonyl, heterocycle, heterocyclealkoxy, heterocyclecarbonyl, heterocycleoxy, heterocyclesulfonyl, hydroxy, hydroxyalkyl, methylenedioxy, nitro, -C(O)N(H)
  • the substituent aryl, the aryl of arylalkoxy, the aryl of arylcarbonyl, the aryl of aryloxy, the aryl of arylsulfonyl, the substituent heteroaryl, the heteroaryl of heteroarylalkyl, the heteroaryl of heteroarylcarbonyl, the substituent heterocycle, the heterocycle of heterocyclecarbonyl, the heterocycle of heterocycleoxy, the heterocycle of heterocyclesulfonyl may be optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkynyl, carboxy, carboxyalkyl, cyano, haloalkyl, halogen, hydroxy, hydroxyalkyl, nitro, R f R g N-, R f R g Nalkyl, R f R g Ncarbonyl and R f R g N
  • arylalkoxy means an aryl group appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • Representative examples of arylalkoxy include, but are not limited to, 2-phenylethoxy, 3-naphth-2-ylpropoxy, and 5-phenylpentyloxy.
  • arylalkoxycarbonyl means an arylalkoxy group appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of arylalkoxycarbonyl include, but are not limited to, benzyloxycarbonyl and naphth-2- ylmethoxy carbonyl .
  • arylalkyl means an aryl group appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of arylalkyl include, but are not limited to, benzyl, 2-phenylethyl and 3-phenylpropyl.
  • arylcarbonyl means an aryl group appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of arylcarbonyl include, but are not limited to, benzoyl and naphthoyl.
  • aryloxy means an aryl group appended to the parent molecular moiety through an oxygen atom.
  • Representative examples of aryloxy include, but are not limited to, phenoxy and tolyloxy.
  • aryloxyalkyl refers to an aryloxy group appended to the parent molecular moiety through an alkyl group, as defined herein.
  • aryloxyimideamide means a •"> « group.
  • arylsulfonyl refers to an aryl group appended to the parent molecular moiety through a sulfonyl group, as defined herein.
  • Representative examples of arylsulfonyl include, but are not limited to, phenylsulfonyl, 4-bromophenylsulfonyl and naphthylsulfonyl.
  • carbonyl means a -C(O)- group.
  • carboxy means a -CO 2 H group.
  • carboxyalkyl means a carboxy group appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of carboxyalkyl include, but are not limited to, carboxymethyl, 2-carboxyethyl, and 3-carboxypropyl.
  • carboxycycloalkyl refers to a carboxy group as defined herein, appended to the parent molecular moiety through a cycloalkyl group as defined herein.
  • combination therapy is defined as the administration of a single pharmaceutical dosage formulation, which comprises two or more therapeutic agents.
  • cyano means a -CN group, attached to the parent molecular moiety through the carbon.
  • cyanoalkyl means a -CN group attached to the parent molecular moiety through an alkyl group.
  • Representative examples of “cyanoalkyl” include, but are not limited to, 3-cyanopropyl, and 4-cyanobutyl.
  • cyanoamidine means a group.
  • cycloalkoxy means a cycloalkyl group appended to the parent molecular moiety through an oxygen atom.
  • Representative examples of cycloalkoxy include, but are not limited to, cyclohexyloxy and cyclopropoxy.
  • cycloalkoxyalkyl means a cycloalkoxy group appended to the parent molecular moiety through an alkyl group, wherein alkyl is as defined herein.
  • Representative examples of cycloalkoxylalkyl include, but are not limited to, cyclobutoxymethyl, cyclopentyloxymethyl, 2-(cyclopentyloxy)ethyl and cyclohexyloxymethyl.
  • cycloalkyl means a monocyclic, bicyclic, or tricyclic ring system.
  • Monocyclic ring systems are exemplified by a saturated cyclic hydrocarbon group containing from 3 to 4 carbon atoms ((C 3 -C 4 )cycloalkyl), 5 to 6 carbon atoms ((C 5 -Ce)cycloalkyl), 3 to 6 carbon atoms ((C 3 -Ce)cycloalkyl), from 7 to 8 carbon atoms ((Cy-C 8 )cycloalkyl), or from 3 to 8 carbon atoms ((C3-Cg)cycloalkyl).
  • monocyclic ring systems include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • Bicyclic ring systems are exemplified by a bridged monocyclic ring system in which two non-adjacent carbon atoms of the monocyclic ring are linked by an alkylene bridge of between one and three additional carbon atoms.
  • bicyclic ring systems include, but are not limited to, bicyclo[3.1.1]heptanyl, bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, bicyclo[5.1.0]octanyl, bicyclo[3.2.2]nonanyl, bicyclo[3.3.1]nonanyl, and bicyclo[4.2. ljnonanyl.
  • Bicyclic ring systems are also exemplified by a monocyclic ring system fused to a phenyl or heteroaryl ring.
  • bicyclic ring systems include, but are not limited to, 1,2,3,4-tetrahydronaphthalenyl, indanyl, and 6,7- dihydro-5H-cyclopenta[c]pyridinyl.
  • the bicyclic cycloalkyl is connected to the parent molecular moiety through any carbon atom contained within the unsaturated cycloalkyl ring.
  • Tricyclic ring systems are exemplified by a bicyclic ring system in which two non-adjacent carbon atoms of the bicyclic ring are linked by a bond or an alkylene bridge of between one and three carbon atoms.
  • tricyc lie-ring systems include, but are not limited to, octahydro-2,5-methanopentalene, tricyclo[3.3.1.0 3 ' 7 ]nonanyl and tricyclo[3.3.1.1 3 ' 7 ]decanyl (adamantanyl).
  • cycloalkyl groups of the present invention are substituted with 0, 1, 2, 3 or 4 substituents selected from the group consisting of alkyl, alkenyl, alkyl-N ⁇ -alkyl, alkylcarbonyl, alkylsulfonyl, alkylthio, aryl, arylalkyl, aryloxyalkyl, arylcarbonyl, arylsulfonyl, carboxyalkyl, carboxycycloalkyl, cyano, cyanoalkyl, cycloalkyl, cycloalkylcarbonyl, cycloalkylsulfonyl, halogen, haloalkyl, heterocyclecarbonyl, heterocyclesulfonyl, heteroaryl, heteroarylalkyl, heterocycle, heterocycleoxyalkyl, -NO 2 , -NR 8 -[C(R 9 R 10 )] p -C(O)-R ⁇ ,
  • R 9 and R 10 are each independently hydrogen, alkyl, carboxy, carboxyalkyl, cycloalkyl, carboxycycloalkyl, aryl, arylalkyl, aryloxyalkyl, heterocycle, heterocyclealkyl, or heterocycleoxyalkyl, or R 9 and R 10 together with the atom to which they are attached form cycloalkyl or heterocycle;
  • R 11 is hydrogen, alkyl, carboxy, carboxyalkyl, cycloalkyl, carboxycycloalkyl, aryl, aryloxy, arylalkyl, aryloxyalkyl, hydroxy, alkoxy, cycloalkyloxy, heterocycleoxy, heterocycle, heterocyclealkyl, heterocycleoxyalkyl, or -N(R 28 R 29 );
  • R 12 and R 13 are each independently hydrogen, alkyl, carboxy, carboxyalkyl, cycloalkyl, carboxycycloalkyl, aryl, arylalkyl, aryloxyalkyl, heterocycle, heterocyclealkyl, heterocycleoxyalkyl or -N(R 28 R 29 ), or R 12 and R 13 together with the atom to which they are attached form cycloalkyl or heterocycle;
  • R 14 is hydrogen, alkyl, carboxy, carboxyalkyl, cycloalkyl, carboxycycloalkyl, aryl,
  • R 15 is hydrogen, alkyl, alkylcarbonyl, carboxyalkyl, cycloalkyl, carboxycycloalkyl, aryl, arylalkyl, aryloxyalkyl, haloalkyl, heterocycle, heterocyclealkyl, or heterocycleoxyalkyl;
  • R 16 and R 17 are each independently hydrogen, alkyl, alkylcarbonyl, carboxyalkyl, cycloalkyl, carboxycycloalkyl, aryl, arylalkyl, aryloxyalkyl, haloalkyl, heterocycle, heterocyclealkyl, heterocycleoxyalkyl, alkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl, formyl, or heterocyclesulfonyl, or R 16 and R 17 together with the atom to which they are attached form a heterocycle;
  • R 18 is hydrogen, alkyl, carboxyalkyl, cycl
  • R 19 and R 20 are each independently hydrogen, alkyl, carboxy, carboxyalkyl, cycloalkyl, cycloalkyloxy, carboxycycloalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, heteroarylalkyl, heterocycle, heterocyclealkyl, heterocycleoxyalkyl, heterocycleoxy, hydroxy, alkoxy, alkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl, heterocyclesulfonyl, or
  • R 21 , R 22 and R 23 are each independently hydrogen, alkyl, carboxyalkyl, carboxycycloalkyl, cycloalkyl, haloalkyl, aryl, heterocycle, or heterocyclealkyl;
  • R 24 and R 25 are each independently hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, carboxyalkyl, carboxycycloalkyl, cycloalkylcarbonyl, cycloalkylsulfonyl, arylcarbonyl, arylsulfonyl, heterocyclecarbonyl, heterocyclesulfonyl, cycloalkyl, aryl, or heterocycle;
  • R 26 and R 27 are each independently hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, carboxyalkyl, carboxycycloalkyl, cycloalkylcarbonyl, cycloalkylsulfonyl, arylcarbonyl, arylsulfonyl, heterocyclecarbonyl, heterocyclesulfonyl, hydroxy, alkoxy, cycloalkyloxy, aryloxy, heterocycleoxy, cycloalkyl, aryl, or heterocycle, or R 26 and R 27 together with the atom to which they are attached form a heterocycle;
  • R 28 and R 29 are each independently at each occurrence hydrogen or alkyl
  • R 30 and R 31 are each independently at each occurrence hydrogen, alkyl, alkylcarbonyl, alkoxy, alkylsulfonyl, aryl, arylcarbonyl, aryloxy, arylsulfonyl, carboxyalkyl, carboxycycloalkyl, cycloalkyl, cycloalkylcarbonyl, cycloalkyloxy, cycloalkylsulfonyl, heteroaryl, heteroarylcarbonyl, heteroaryloxy, heteroarylsulfonyl, heterocycle, heterocyclecarbonyl, heterocycleoxy, heterocyclesulfonyl, or hydroxy, or R 30 and R 31 taken together with the atom to which they are attached form heteroaryl or heterocycle; and
  • R 32 and R 33 are each independently at each occurrence selected from the group consisting of hydrogen, alkyl, alkoxy, alkylsulfonyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, arylsulfonyl, alkyl-NH-alkyl, aryl-NH-alkyl, arylalkyl, haloalkyl, aryl-heterocycle, carboxy, carboxyalkyl, carboxycycloalkyl, cycloalkyl, cycloalkyloxy, cycloalkylsulfonyl, heteroaryl, heteroarylalkyl, heteroaryloxyalkyl, heteroaryloxy, heteroarylsulfonyl, heterocycle, heterocycle-NH-alkyl, heterocyclealkyl, heterocycle -heterocycle, heterocycleoxyalkyl, heterocycleoxy, heterocyclesulfonyl, and hydroxy, or R 32 and R 33 taken together
  • cycloalkylalkyl means a cycloalkyl group appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of cycloalkylalkyl include, but are not limited to, cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl, and cycloheptylmethyl.
  • cycloalkylcarbonyl means cycloalkyl group appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of cycloalkylcarbonyl include, but are not limited to, cyclopropylcarbonyl, 2- cyclobutylcarbonyl, and cyclohexylcarbonyl.
  • cycloalkylsulfonyl refers to cycloalkyl group appended to the parent molecular moiety through a sulfonyl group, as defined herein.
  • Representative examples of cycloalkylsulfonyl include, but are not limited to, cyclohexylsulfonyl and cyclobutylsulfonyl.
  • halo or halogen means -Cl, -Br, -I or -F.
  • haloalkoxy means at least one halogen appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • Representative examples of haloalkoxy include, but are not limited to, fluoroalkoxy, chloroalkoxy, bromoalkoxy and iodoalkoxy, such as fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2-fluoroethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, and pentafluoroethoxy.
  • haloalkyl means at least one halogen appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of haloalkyl include, but are not limited to, difluoromethyl, chloromethyl, 2-fluoroethyl, trifluoromethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, and 2-chloro-3-fluoropentyl.
  • halocycloalkyl means at least one halogen appended to the parent molecular moiety through a cycloalkyl group, as defined herein.
  • Representative examples of halocycloalkyl include, but are not limited to, fluorocyclohexyl, bromocyclopropyl, and trans-2,3-dichlorocyclopentyl.
  • halocycloalkylalkyl means a halocycloalkyl group as defined herein, attached to the parent molecular moiety through an alkyl group.
  • Representative examples of halocycloalkylalkyl include, but are not limited to, (4-fluorocyclohexyl)methyl, (2,2- difluorocyclobutyl)methyl and the like.
  • halothioalkoxy means at least one halogen appended to the parent molecular moiety through a thioalkoxy group, as defined herein.
  • Representative examples of halothioalkoxy include, but are not limited to, 2-chloroethylsulfane and trifluoromethy lsulfane .
  • heteroaryl means a monocyclic heteroaryl or a bicyclic heteroaryl.
  • the monocyclic heteroaryl is a 5 or 6 membered ring that contains at least one heteroatom selected from the group consisting of nitrogen, oxygen and sulfur.
  • the 5 membered ring contains two double bonds and the 6 membered ring contains three double bonds.
  • the 5 or 6 membered heteroaryl is connected to the parent molecular moiety through any carbon atom or any substitutable nitrogen atom contained within the heteroaryl, provided that proper valance is maintained.
  • monocyclic heteroaryl include, but are not limited to, furyl, imidazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, tetrazolyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, and triazinyl.
  • the bicyclic heteroaryl consists of a monocyclic heteroaryl fused to a phenyl, or a monocyclic heteroaryl fused to a cycloalkyl, or a monocyclic heteroaryl fused to a cycloalkenyl, or a monocyclic heteroaryl fused to a monocyclic heteroaryl.
  • the bicyclic heteroaryl is connected to the parent molecular moiety through any carbon atom or any substitutable nitrogen atom contained within the bicyclic heteroaryl, provided that proper valance is maintained.
  • bicyclic heteroaryl include, but are not limited to, azaindolyl, benzimidazolyl, benzofuranyl, benzoxadiazolyl, benzoisoxazole, benzoisothiazole, benzooxazole, 1,3-benzothiazolyl, benzothiophenyl, cinnolinyl, furopyridine, indolyl, indazolyl, isobenzofuran, isoindolyl, isoquinolinyl, naphthyridinyl, oxazolopyridine, lH-pyrrolo[2,3-b]pyridinyl, quinolinyl, quinoxalinyl and thienopyridinyl.
  • the heteroaryl groups are optionally substituted with 1 , 2, 3 or 4 substituents independently selected from the group consisting of acyloxy, alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfonyl, alkylthio, alkynyl, amido, aryl, aryloxy, carboxy, carboxyalkyl, cyano, cyanoalkyl, cycloalkyl, cycloalkoxy, formyl, haloalkoxy, haloalkyl, halogen, halothioalkoxy, heteroaryl, thioalkoxy, thiocycloalkoxy, thioaryloxy, nitro, and -NR 96 R 97 , wherein R 96 and R 97 are independently hydrogen, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfonyl, aryl,
  • heteroarylalkoxy means a heteroaryl group appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • Representative examples of heteroarylalkoxy include, but are not limited to, fur-3-ylmethoxy, lH-imidazol-2-ylmethoxy, lH-imidazol-4-ylmethoxy, l-(pyridin-4-yl)ethoxy, pyridin-3- ylmethoxy, 6-chloropyridin-3-ylmethoxy, pyridin-4-ylmethoxy, (6-(trifluoromethyl)pyridin- 3 -yl)methoxy , (6-(cyano)pyridin-3 -yl)methoxy , (2-(cyano)pyridin-4-yl)methoxy , (5 -(cyano)pyridin-2-yl)methoxy , (2-(chloro)pyridin-4-
  • heteroarylcarbonyl means a heteroaryl group appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of heteroarylcarbonyl include, but are not limited to, fur-3-ylcarbonyl, lH-imidazol-2- ylcarbonyl, lH-imidazol-4-ylcarbonyl, pyridin-3-ylcarbonyl, 6-chloropyridin-3-ylcarbonyl, pyridin-4-ylcarbonyl, (6-(trifluoromethyl)pyridin-3 -yl)carbonyl, (6-(cyano)pyridin-3 - yl)carbonyl, (2-(cyano)pyridin-4-yl)carbonyl, (5 -(cyano)pyridin-2-yl)carbonyl, (2-(chloro)pyridin-4-yl)carbonyl, pyrimidin-5 -ylcarbonyl, pyrimidin
  • heterocycle or “heterocyclic” means a monocyclic heterocycle, a bicyclic heterocycle, or tricyclic heterocycle.
  • the monocyclic heterocycle is a 3, 4, 5, 6 or 7 membered ring containing at least one heteroatom independently selected from the group consisting of O, N, and S.
  • the 3- or 4-membered ring contains 1 heteroatom selected from the group consisting of O, N and S.
  • the 5-membered ring contains zero or one double bond and one, two or three heteroatoms selected from the group consisting of O, N and S.
  • the 6- or 7-membered ring contains zero, one, or two double bonds provided that the ring, when taken together with a substituent, does not tautomerize with a substituent to form an aromatic ring and one, two, three, or four heteroatoms selected from the group consisting of O, N and S.
  • the monocyclic heterocycle is connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the monocyclic heterocycle.
  • monocyclic heterocycle include, but are not limited to, azetidinyl, azepanyl, aziridinyl, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl, 1,3-dithiolanyl, 1,3-dithianyl, imidazolinyl, imidazolidinyl, isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyr
  • the bicyclic heterocycle is a monocyclic heterocycle fused to a phenyl group, a monocyclic heterocycle fused to a cycloalkyl, a monocyclic heterocycle fused to a cycloalkenyl, or a monocyclic heterocycle fused to a monocyclic heterocycle.
  • the bicyclic heterocycle is connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the monocyclic heterocycle.
  • bicyclic heterocycle include, but are not limited to, azabicyclo[3.2.0]hept-3-yl, l-azabicyclo[2.2.2]octyl (quinuclidinyl), 1,3-benzodioxolyl, 1,3- benzodithiolyl, 2,3-dihydro-l,4-benzodioxinyl, 3,7-diazabicyclo[3.3.1]nonanyl, 3,9- diazabicyclo[4.2.1]nonanyl, 2,3-dihydro-l-benzofuranyl, 2,3-dihydro-l-benzothienyl, 2,3- dihydro-lH-indolyl, hexahydropyrrolo[3,4- ⁇ ]pyrrol-l(2H)-yl, indolinyl, isoindolinyl, 2,3,4,5- tetrahydro-lH-3-benzazepinyl, octa
  • tricyclic heterocyclic systems include, but are not limited to, aza-adamantanyl, oxa-adamantanyl, and 7,8,9, 10-tetrahydro- 6H-[l,3]dioxolo[4,5-g][3]benzazepinyl.
  • the heterocycles are substituted with 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9 substituents independently selected from acyl, acyloxy, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxyimino, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylsulfonyl, alkylthio, alkynyl, amido, aryl, arylalkoxycarbonyl, arylalkyl, aryloxy, aryloxyalkyl, carboxy, cyano, cyanoalkyl, cycloalkyl, formyl, haloalkoxy, haloalkyl, halogen, heteroaryl, heteroarylalkyl, heteroarylcarbonyl, heteroaryloxyalkyl, hydroxy, hydroxyalkyl, mercapto, nitro, oxo, - alkylNR 98 R", -
  • heterocyclealkoxy refers to a heterocycle appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • Representative examples of heterocyclealkoxy include, but are not limited, 2-morpholin-4-ylethoxy, 2- morpholin-4-ylethoxy, and (tetrahydrofuran-2-yl)methoxy.
  • heterocyclealkyl means a heterocycle appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of heterocyclealkyl include, but are not limited, (pyrrolidin-2-yl) methyl, 2-(morpholin-4- yl)ethyl, and (tetrahydrofuran-3-yl)methyl.
  • heterocyclecarbonyl refers to a heterocycle appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of heterocyclecarbonyl include, but are not limited to, 1-piperidinylcarbonyl, A- morpholinylcarbonyl, pyridin-3-ylcarbonyl and quinolin-3-ylcarbonyl.
  • heterocycle-heterocycle means a heterocycle appended to the parent molecular moiety through a second heterocycle, as defined herein.
  • heterocycleoxyalkyl refers to a heterocycleoxy appended to the parent molecular moiety through an alkyl group, as defined herein.
  • heterocyclesulfonyl refers to a heterocycle appended to the parent molecular moiety through a sulfonyl group, as defined herein.
  • Representative examples of heterocyclesulfonyl include, but are not limited to, 1-piperidinylsulfonyl, A- morpholinylsulfonyl, pyridin-3-ylsulfonyl and quinolin-3-ylsulfonyl.
  • hydroxy or "hydroxyl” means an -OH group.
  • hydroxyalkyl means at least one hydroxy group appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of hydroxyalkyl include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 2-methyl-2- hydroxyethyl, 3-hydroxypropyl, 2,3-dihydroxypentyl, and 2-ethyl-4-hydroxyheptyl.
  • hydroxyimideamide means a group.
  • mercapto means a -SH group.
  • nitro means a -NO 2 group.
  • parenterally refers to modes of administration, including intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous, intraarticular injection and infusion.
  • salt refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit/risk ratio and effective for their intended use.
  • Pharmaceutically acceptable salts are well-known in the art. The salts can be prepared in situ during the final isolation and purification of the compounds of the invention or separately by reacting a free base function with a suitable organic acid.
  • Representative acid addition salts include, but are not limited to acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, phosphate, glutamate, bicarbonate, p-toluenesulfonate and undecanoate.
  • the basic nitrogen- containing groups can be quaternized with such agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates such as dimethyl, diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; arylalkyl halides such as benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained.
  • lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides
  • dialkyl sulfates such as dimethyl, diethyl, dibutyl and diamyl sulfates
  • long chain halides such as
  • acids which can be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, hydrobromic acid, sulfuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid, and citric acid.
  • Basic addition salts can be prepared in situ during the final isolation and purification of compounds of this invention by reacting a carboxylic acid-containing moiety with a suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation or with ammonia or an organic primary, secondary or tertiary amine.
  • Pharmaceutically acceptable salts include, but are not limited to, cations based on alkali metals or alkaline earth metals such as lithium, sodium, potassium, calcium, magnesium, and aluminum salts, and the like, and nontoxic quaternary ammonia and amine cations including ammonium, tetramethylammonium, tetraethylammonium, methylammonium, dimethylammonium, trimethylammonium, triethylammonium, diethylammonium, ethylammonium and the like.
  • Other representative organic amines useful for the formation of base addition salts include ethylenediammonium, ethanolammonium, diethanolammonium, piperidinium, and piperazinium.
  • esters of compounds of the invention which hydro lyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof.
  • examples of pharmaceutically acceptable, non-toxic esters of the invention include, but are not limited to, Ci-C 6 alkyl esters and C5-C7 cycloalkyl esters.
  • Esters of the compounds of formula (I) can be prepared according to conventional methods. Pharmaceutically acceptable esters can be appended onto hydroxy groups by reaction of the compound that contains the hydroxy group with acid and an alkylcarboxylic acid such as acetic acid, or with acid and an arylcarboxylic acid such as benzoic acid.
  • the pharmaceutically acceptable esters are prepared from compounds containing the carboxylic acid groups by reaction of the compound with base such as triethylamine and an alkyl halide, for example with methyl iodide, benzyl iodide, cyclopentyl iodide or alkyl triflate. They also can be prepared by reaction of the compound with an acid such as hydrochloric acid and an alcohol such as ethanol or methanol.
  • amide refers to non-toxic amides of the invention derived from ammonia, primary C1-C3 alkyl amines, primary C 4 -C 6 alkyl amines, secondary C1-C2 dialkyl amines and secondary C 3 -C 6 dialkyl amines.
  • the amine can also be in the form of a 5- or 6-membered heterocycle containing one nitrogen atom.
  • Amides of the compounds of formula (I) can be prepared according to conventional methods.
  • Pharmaceutically acceptable amides can be prepared from compounds containing primary or secondary amine groups by reaction of the compound that contains the amino group with an alkyl anhydride, aryl anhydride, acyl halide, or aroyl halide.
  • the pharmaceutically acceptable amides are prepared from compounds containing the carboxylic acid groups by reaction of the compound with base such as triethylamine, a dehydrating agent such as dicyclohexyl carbodiimide or carbonyl diimidazole, and an alkyl amine, dialkylamine, for example with methylamine, diethylamine, and piperidine.
  • compositions can contain a compound of the invention in the form of a pharmaceutically acceptable prodrug.
  • prodrug or "prodrug” represents those prodrugs of the compounds of the invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use.
  • Prodrugs of the invention can be rapidly transformed in vivo to a parent compound of formula (I), for example, by hydrolysis.
  • a thorough discussion is provided in Higuchi et al., Pro-drugs as Novel Delivery Systems, V. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press (1987).
  • pharmaceutically acceptable carrier means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
  • materials which can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols such a propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isot
  • sulfonyl means a -SO 2 - group.
  • therapeutically effective amount means a sufficient amount of the compound to treat disorders, at a reasonable benefit/risk ratio applicable to any medical treatment.
  • therapeutically suitable excipient generally refers to pharmaceutically suitable, solid, semi-solid or liquid fillers, diluents, encapsulating material, formulation auxiliary and the like.
  • terapéuticaally suitable metabolite generally refers to a pharmaceutically active compound formed by the in vivo biotransformation of compounds of formula I.
  • thioalkoxy refers to an alkyl group appended to the parent molecular moiety through a sulfur atom.
  • Representative examples of thioalkoxy include, but are not limited to, methylthio, ethylthio, te/t-butylthio, and hexylthio.
  • thioamide means a -" ⁇ group.
  • thiocyloalkoxy refers to a cycloalkyl group appended to the parent molecular moiety through a sulfur atom.
  • Representative examples of thiocycloalkoxy include, but are not limited to, cyclopentylsulfane and cyclohexylsulfane.
  • thioaryloxy means an aryl group appended to the parent molecular moiety through a sulfur atom.
  • Representative examples of thioaryloxy include, but are not limited to, thiophenoxy and tolylsulfane.
  • An embodiment is directed toward a compound of formula (I)
  • L is -(CH 2 V, -(CR 38 R 3 Vx-(CR 38 R 3 V or -(CR 38 R 39 ) m -X-(CR 38 R 39 ) n -Y-;
  • m is independently at each occurrence 0, 1, or 2;
  • n is independently at each occurrence 0, 1, or 2;
  • R 1 is cycloalkyl or heterocycle;
  • R 2 is hydrogen, alkyl, or aryl; or R 1 and R 2 together with the atoms to which they are attached form a heterocycle; or R 2 and R 3 together with the atoms to which they are attached form a heterocycle;
  • R 3 and R 4 are independently hydrogen, alkyl or cycloalkyl; or R 3 and R 4 together with the atom to which they are attached form a cycloalkyl, heterocycle, heteroaryl, or aryl;
  • R 5 is hydrogen, alkyl, amino, aryl, cycloalkyl, heteroaryl, or heterocycle provided R 5 is other than amino when L is -(CR 38 R 39 ) m -X-(CR 38 R 39 ) n -Y-; or R 4 and R 5 together with the atoms to which they are attached form a cycloalkyl or heterocycle;
  • X is -O-, -S-, -S(O)-, -S(O) 2 -, -NR 36 -, or -CR 36 R 37 -;
  • Y is O or NR 40 ;
  • R 36 and R 37 are independently at each occurrence hydrogen or alkyl; or R 36 and R 2 together with the atoms to which they are attached form a heterocycle;
  • R 38 , R 39 and R 40 are independently at each occurrence hydrogen or alkyl
  • W is N-CN, N-OR 6 , N-R 6 , or S; and R 6 is hydrogen, alkyl or aryl; or a pharmaceutically acceptable salt, ester, amide, N-oxide or prodrug thereof.
  • Another embodiment is a compound of formula (I), wherein R 1 is cycloalkyl.
  • Another embodiment is a compound of formula (I), wherein R 1 is heterocycle.
  • Another embodiment is a compound of formula (I), wherein R 1 is a cycloalkyl or heterocycle selected from the group consisting of
  • Another embodiment is a compound of formula (I), wherein R 1 is a cycloalkyl or heterocycle selected from the group consisting of
  • Another embodiment is a compound of formula (I), wherein R 1 is a cycloalkyl or heterocycle selected from the group consisting of
  • Another embodiment is a compound of formula (I), wherein R 1 is a cycloalkyl selected from the group consisting of
  • Another embodiment is a compound of formula (I), wherein R 1 is a cycloalkyl selected from the group consisting of
  • Another embodiment is a compound of formula (I), wherein R 1 is a cycloalkyl selected from the group consisting of
  • Another embodiment is a compound of formula (I), wherein R 1 is a cycloalkyl that is
  • Another embodiment is a compound of formula (I), wherein R 1 is a cycloalkyl that is formula (iia)
  • Another embodiment is a compound of formula (I), wherein R 1 is a heterocycle selected from the group consisting of
  • Another embodiment is a compound of formula (I), wherein R 1 is a heterocycle selected from the group consisting of
  • Another embodiment is a compound of formula (I), wherein R 1 is a heterocycle that is azaadamantane.
  • R 1 is cycloalkyl substituted with 0, 1, 2, 3 or 4 substituents selected from the group consisting of alkyl, alkenyl, alkyl-NH-alkyl, alkylcarbonyl, alkylsulfonyl, alkylthio, aryl, arylalkyl, aryloxyalkyl, arylcarbonyl, arylsulfonyl, carboxyalkyl, carboxycycloalkyl, cyano, cyanoalkyl, cycloalkyl, cycloalkylcarbonyl, cycloalkylsulfonyl, halogen, haloalkyl, heterocyclecarbonyl, heterocyclesulfonyl, heteroaryl, heteroarylalkyl, heterocycle, heterocycleoxyalkyl, -NO 2 , -NR 8 -[C(R 9 R 10 )] p -C(
  • Another embodiment is a compound of formula (I), wherein R 1 is substituted with 0, 1, 2, 3 or 4 substituents selected from the group consisting of alkylsulfonyl, cyano, halogen, -C(R 12 R 13 )-C(O)-R 14 , -OR 15 , -CO 2 R 18 , -C(O)-N(R 19 R 20 ), and -S(O) 2 -N(R 32 R 33 ).
  • Another embodiment is a compound of formula (I), wherein R 1 is substituted with 0, 1 or 2 substituents selected from the group consisting of fluorine, methylsulfonyl, cyano, -OH, -OCH 3 , -OCF 3 , -OCHF 2 , -CO 2 H, -CH 2 -CO 2 H, -CH(CH 3 )-CO 2 H, -C(CH 3 ) 2 -CO 2 H, -CHF 2 , -CH(CH 3 )(OH), -C(CHs) 2 (OH), -CH 2 OH, -C(O)-NH 2 , and -S(O) 2 -NH 2 .
  • R 1 is substituted with 0, 1 or 2 substituents selected from the group consisting of fluorine, methylsulfonyl, cyano, -OH, -OCH 3 , -OCF 3 , -OCHF 2 , -CO 2 H, -CH 2
  • Another embodiment is a compound of formula (I), wherein R 1 is substituted with at least one substituent selected from the group consisting of fluorine, methylsulfonyl, cyano, -OH, -CO 2 H, -CH 2 -CO 2 H, -CH(CH 3 )-CO 2 H, -C(CH 3 ) 2 -CO 2 H,-CH(CH 3 )(OH), -C(O)-NH 2 , and -S(O) 2 -NH 2 .
  • R 1 is substituted with at least one substituent selected from the group consisting of fluorine, methylsulfonyl, cyano, -OH, -CO 2 H, -CH 2 -CO 2 H, -CH(CH 3 )-CO 2 H, -C(CH 3 ) 2 -CO 2 H,-CH(CH 3 )(OH), -C(O)-NH 2 , and -S(O) 2 -NH 2 .
  • Another embodiment is a compound of formula (I), wherein R 1 is substituted with O, 1, 2, 3 or 4 substituents selected from the group consisting of alkylsulfonyl, cyano, -OR 15 , -CO 2 R 18 , -C(O)-N(R 19 R 20 ), and -S(O) 2 -N(R 32 R 33 ).
  • Another embodiment is a compound of formula (I), wherein R 2 is hydrogen, alkyl or aryl.
  • Another embodiment is a compound of formula (I), wherein R 2 is hydrogen.
  • Another embodiment is a compound of formula (I), wherein R 2 is alkyl.
  • Another embodiment is a compound of formula (I), wherein R 2 is aryl.
  • Another embodiment is a compound of formula (I), wherein R 1 and R 2 together with the atoms to which they are attached form a heterocycle.
  • Another embodiment is a compound of formula (I), wherein R 3 and R 4 are each hydrogen.
  • Another embodiment is a compound of formula (I), wherein R 3 and R 4 are each alkyl.
  • Another embodiment is a compound of formula (I), wherein R 3 is hydrogen and R 4 is alkyl.
  • Another embodiment is a compound of formula (I), wherein R 2 and R 3 together with the atoms to which they are attached form a heterocycle.
  • Another embodiment is a compound of formula (I), wherein R 2 and R 3 together with the atoms to which they are attached form a 5-membered heterocycle, and R 4 is hydrogen; and is represented by formula (II):
  • R 34 and R 35 are independently hydrogen or alkyl; or R 34 and R 35 together with the atom to which they are attached form a cycloalkyl, and r is 1 or 2.
  • Another embodiment is a compound of formula (I), wherein R 3 and R 4 together with the atom to which they are attached form a cycloalkyl, heterocycle, heteroaryl or aryl.
  • Another embodiment is a compound of formula (I), wherein R 3 and R 4 together with the atom to which they are attached form a cycloalkyl, heterocycle, heteroaryl or aryl; and L is a bond (i.e., n is 0, when L is -(CH 2 ) n -).
  • Another embodiment is a compound of formula (I), wherein R 3 and R 4 together with the atom to which they are attached form a cycloalkyl or heterocycle.
  • Another embodiment is a compound of formula (I), wherein R 3 and R 4 together with the atom to which they are attached form a cycloalkyl, wherein cycloalkyl is (C 3 -C 6 )cycloalkyl.
  • Another embodiment is a compound of formula (I), wherein R 3 and R 4 together with the atom to which they are attached form a heteroaryl or aryl.
  • Another embodiment is a compound of formula (I), wherein R 4 and R 5 together with atoms to which they are attached form a cycloalkyl or heterocycle.
  • Another embodiment is a compound of formula (I), wherein R 3 is hydrogen, R 4 and R 5 together with atoms to which they are attached form a cycloalkyl or heterocycle.
  • Another embodiment is a compound of formula (I), wherein R 3 is hydrogen, R 4 and
  • R 5 together with atoms to which they are attached form a heterocycle.
  • Another embodiment is a compound of formula (I), wherein L is
  • Another embodiment is a compound of formula (III), wherein n is 0, and R 5 is aryl or heteroaryl.
  • Another embodiment is a compound of formula (IV), wherein R 5 is aryl or heteroaryl.
  • Another embodiment is a compound of formula (I), wherein L is
  • Another embodiment is a compound of formula (I), wherein R 5 is amino, aryl, cycloalkyl, heteroaryl, or heterocycle.
  • Another embodiment is a compound of formula (I), wherein R 5 is cycloalkyl, wherein the cycloalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkoxy, alkyl, aryloxy, aryl, carboxy, carboxyalkyl, cycloalkyl, cycloalkoxy, halogen, haloalkoxy, haloalkyl, halothioalkoxy, heteroaryl, hydroxyl, mercapto, thioalkoxy, thiocycloalkoxy, and thioaryloxy.
  • Another embodiment is a compound of formula (I), wherein R 5 is amino.
  • R 5 is aryl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkoxy, alkyl, aryloxy, carboxy, carboxyalkyl, cycloalkyl, cycloalkoxy, cyano, halogen, haloalkoxy, haloalkyl, halothioalkoxy, heteroaryl, hydroxyl, mercapto, thioalkoxy, thiocycloalkoxy, and thioaryloxy.
  • R 5 is phenyl optionally substituted with 1 , 2 or 3 substituents independently selected from the group consisting of alkyl, cyano, halogen, haloalkyl and heteroaryl.
  • R 5 is heteroaryl selected from pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, wherein the heteroaryl is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkoxy, alkyl, aryl, aryloxy, carboxy, carboxyalkyl, cycloalkyl, cycloalkoxy, cyano, halogen, haloalkoxy, haloalkyl, halothioalkoxy, hydroxyl, mercapto, thioalkoxy, thiocycloalkoxy, and thioaryloxy.
  • Another embodiment is a compound of formula (I), wherein R 5 is pyridinyl, wherein the pyridinyl is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkyl, cyano, halogen, and haloalkyl.
  • R 5 is heterocycle selected from azabicyclo[3.2.0]hept-3-yl, piperazinyl, piperidinyl, morpholinyl, thiomorpholinyl, wherein the heterocycle is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkoxy, alkyl, aryl, cyano, halogen, haloalkyl, and heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted with halogen or haloalkyl.
  • Another embodiment is a compound of formula (I), wherein R 5 is heterocycle selected from piperazinyl or piperidinyl, wherein the heterocycle is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkyl, aryl, cyano, halogen, haloalkyl, and heteroaryl, wherein the aryl is phenyl and the heteroaryl is pyridinyl each optionally substituted with halogen or haloalkyl.
  • Another embodiment is a compound of formula (I), wherein L is -(CH 2 )D-, wherein n is 0, 1, or 2.
  • Another embodiment is a compound of formula (I), wherein L is -(CH 2 )D-, wherein n is O.
  • Another embodiment is a compound of formula (I), wherein L is -(CH 2 ) n -, wherein n is 1.
  • Another embodiment is a compound of formula (I), wherein L is -(CH 2 ) m -X-(CH 2 ) n -, wherein m is 0 and n is 0.
  • Another embodiment is a compound of formula (I), wherein L is -(CH 2 ) m -X-(CH 2 ) n -, wherein m is 0 and n is 1.
  • Another embodiment is a compound of formula (I), wherein L is -(CH 2 ) m -X-(CH 2 ) n -, wherein m is 0 and n is 2.
  • Another embodiment is a compound of formula (I), wherein L is -(CH 2 ) m -X-(CH 2 ) n -, wherein m is 1 and n is 0.
  • Another embodiment is a compound of formula (I), wherein L is -(CH 2 ) m -X-(CH 2 ) n -, wherein m is 1 and n is 1.
  • Another embodiment is a compound of formula (I), wherein L is -(CH 2 ) m -X-(CH 2 ) n -, wherein m is 1 and n is 2.
  • Another embodiment is a compound of formula (I), wherein L is -(CH 2 ) m -X-(CH 2 ) n -, wherein m is 2 and n is 0.
  • Another embodiment is a compound of formula (I), wherein L is -(CH 2 ) m -X-(CH2)n-, wherein m is 2 and n is 1.
  • Another embodiment is a compound of formula (I), wherein L is -(CH 2 ) m -X-(CH2)n-, wherein m is 2 and n is 2.
  • Another embodiment is a compound of formula (I), wherein L is -(CH 2 )m-X-(CH2) n -, wherein X is -O- .
  • Another embodiment is a compound of formula (I), wherein L is -(CH 2 ) m -X-(CH2)n-, wherein X is -S-.
  • Another embodiment is a compound of formula (I), wherein L is -(CH 2 ) m -X-(CH2)n-, wherein X is -S(O)-.
  • Another embodiment is a compound of formula (I), wherein L is -(CH 2 ) m -X-(CH2)n-, wherein X is -S(O) 2 -.
  • Another embodiment is a compound of formula (I), wherein L is -(CH 2 )m-X-(CH 2 )n-, wherein X is -NR 36 -.
  • Another embodiment is a compound of formula (I), wherein L is -(CH 2 )m-X-(CH 2 )n-, wherein X is -CR 36 R 37 -.
  • Another embodiment is a compound of formula (I), wherein L is -(CH 2 )m-X-(CH 2 )n-, wherein X is -NR 36 -; wherein R 36 is hydrogen or alkyl.
  • Another embodiment is a compound of formula (I), wherein L is -(CH 2 )m-X-(CH 2 )n-, wherein X is -CR 36 R 37 -; wherein R 36 and R 37 are independently hydrogen or alkyl.
  • Another embodiment is a compound of formula (I), wherein L is a bond (i.e., n is 0, when L is -(CH 2 ) n -) and R 5 is amino.
  • R 5 is aryl or heteroaryl.
  • R 5 is heterocycle.
  • Another embodiment is a compound of formula (I), wherein L is -(CH 2 ) m -X-(CH 2 ) n -Y-, wherein X is -CR 36 R 37 - and Y is O or NCH 3 , n is 1 , and R 5 is aryl or heteroaryl.
  • Another embodiment is a compound of formula (I), wherein W is N-CN.
  • Another embodiment is a compound of formula (I), wherein W is S.
  • Another embodiment is a compound of formula (I), wherein W is N-R 6 , wherein R 6 is hydrogen, alkyl or aryl.
  • Another embodiment is a compound of formula (I), wherein W is N-R 6 , wherein R 6 is hydrogen or alkyl.
  • AAnnootthheerr eermbodiment is a compound of formula (I), wherein W is N-OR 6 , wherein R 6 is hydrogen, alkyl or aryl.
  • Another embodiment is a compound of formula (I), wherein W is N-OR 6 , wherein R 6 is hydrogen, or alkyl.
  • R 1 is adamantyl (ii)
  • R 2 is hydrogen
  • R 3 and R 4 are each methyl
  • R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl
  • W is N-CN
  • L is -(CH2) m -X-(CH2) n -, wherein m and n are both 0 and X is O.
  • R 1 is adamantyl (ii) optionally substituted with -OR 15 wherein R 15 is hydrogen, R 2 is hydrogen, R 3 and R 4 are each methyl, R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl, W is N-CN, and L is -(CH 2 ) m -X-(CH2)n- , wherein m and n are both 0 and X is O.
  • R 1 is adamantyl (ii) optionally substituted with -OR 15 wherein R 15 is hydrogen, R 2 is hydrogen, R 3 and R 4 are each alkyl, R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, haloalkyl, cyano, methoxy or haloalkyl, W is N-R 6 , R 6 is hydrogen, and L is -(CH 2 ) m -X-(CH 2 ) n -, wherein m is 0 and n is 0 or 1 and X is O.
  • R 1 is adamantyl (ii) optionally substituted with -OR 15 wherein R 15 is hydrogen, R 2 is hydrogen, R 3 and R 4 are both hydrogen, R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from alkyl, halogen, cyano, methoxy or haloalkyl, W is N-CN, and L is -(CH 2 )D-, wherein n is 1.
  • R 1 is adamantyl (ii) optionally substituted with -OR 15 wherein R 15 is hydrogen, R 2 is hydrogen, R 3 and R 4 are each alkyl, R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl, W is N-CN, and L is -(CH 2 ) n -, wherein n is 1.
  • R 1 is adamantyl (ii) optionally substituted with -OR 15 wherein R 15 is hydrogen, R 2 is hydrogen, R 3 and R 4 are each alkyl, R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl, R 6 is hydrogen, W is NR 6 , and L is -(CH 2 ) n -, wherein n is 1.
  • R 1 is adamantyl (ii) optionally substituted with -OR 15 wherein R 15 is hydrogen, R 2 is hydrogen, R 3 and R 4 are each methyl, R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl, W is N-CN, and L is -(CH 2 ) m -X-(CH2)n- , wherein m and n are each 0 and X is O.
  • R 1 is adamantyl (ii) optionally substituted with -OR 15 wherein R 15 is hydrogen, R 2 is hydrogen, R 3 and R 4 are each hydrogen, R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl, W is N-CN, and L is -(CH 2 ) m -X-(CH2)n- , wherein m and n are each 0 and X is O.
  • R 1 is adamantyl (ii) optionally substituted with -OR 15 wherein R 15 is hydrogen, R 2 is hydrogen, R 3 and R 4 are each hydrogen, R 5 is pyridinyl optionally substituted with halogen, W is N-CN, and L is -(CH 2 ),,-, wherein n is 1.
  • R 1 is adamantyl (ii) optionally substituted with -OR 15 wherein R 15 is hydrogen, R 2 is hydrogen, R 3 and R 4 taken together with the atom to which they are attached are (C 3 -Ce)cycloalkyl, R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl, W is N-CN, and L is -(CH 2 ) n -, wherein n is 0.
  • R 1 is adamantyl (ii) optionally substituted with -OR 15 wherein R 15 is hydrogen, R 2 is hydrogen, R 3 and R 4 taken together with the atom to which they are attached are (C 3 -Ce)cycloalkyl, R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl, W is N-CN, and L is -(CH 2 ) m -X-(CH 2 ) n -, wherein m and n are each 0 and X is O.
  • R 1 is adamantyl (ii) optionally substituted with -OR 15 wherein R 15 is hydrogen, R 2 is hydrogen, R 3 and R 4 are each alkyl, R 5 is heteroaryl optionally substituted with halogen or haloalkyl, W is N-CN, and L is -(CH2)m-X-(CH 2 )n-, wherein m is 0 and n is 0, and X is O.
  • Another embodiment is a compound of formula (I), wherein R 1 is adamantyl (ii) optionally substituted with alkylsulfonyl, R 2 is hydrogen, R 3 and R 4 are each alkyl, R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl, W is S, and L is -(CH 2 ) m -X-(CH2)n-, wherein m and n are each 0 and X is O.
  • Another embodiment is a compound of formula (I), wherein R 1 is adamantyl (ii) optionally substituted with alkylsulfonyl, R 2 is hydrogen, R 3 and R 4 are each alkyl, R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl, R 6 is alkyl, W is N-OR 6 , and L is -(CH 2 ) m -X-(CH 2 )n-, wherein m and n are each 0 and X is O.
  • Another embodiment is a compound of formula (I), wherein R 1 is adamantyl (ii) optionally substituted with alkylsulfonyl, R 2 is hydrogen, R 3 and R 4 are each alkyl, R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl, W is N-CN, and L is -(CH 2 )m-X-(CH2) n -, wherein m and n are each O and X is O.
  • Another embodiment is a compound of formula (I), wherein R 1 is adamantyl (ii) optionally substituted with alkylsulfonyl, R 2 is hydrogen, R 3 and R 4 are each alkyl, R 5 is heteroaryl optionally substituted with halogen or haloalkyl, W is N-CN, and L is -(CH2)m-X-(CH 2 )n-, wherein m is 0 and n is 0, and X is O.
  • R 1 is adamantyl (ii) optionally substituted with alkylsulfonyl
  • R 2 is hydrogen
  • R 3 and R 4 are each alkyl
  • R 5 is heteroaryl optionally substituted with halogen or haloalkyl
  • W is N-CN
  • L is -(CH2)m-X-(CH 2 )n-, wherein m is 0 and n is 0, and X is O.
  • R 1 is adamantyl (ii) optionally substituted with -S(O) 2 -N(R 32 R 33 ),
  • R 2 is hydrogen
  • R 3 and R 4 are each alkyl
  • R 5 is phenyl optionally substituted withl or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl
  • W is N-CN
  • L is -(CH 2 )m-X-(CH 2 )n-, wherein m and n are each 0 and X is O.
  • R 1 is adamantyl (ii) optionally substituted with -S(O) 2 -N(R 32 R 33 ),
  • R 2 is hydrogen
  • R 3 and R 4 are each alkyl
  • R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, haloalkoxy, methoxy or haloalkyl
  • W is N-CN or S
  • L is -(CH 2 ) m -X-(CH 2 )n-, wherein m and n are each 0 and X is O.
  • R 1 is adamantyl (ii) optionally substituted with -S(O) 2 -N(R 32 R 33 ),
  • R 2 is hydrogen
  • R 3 and R 4 are each alkyl
  • R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl
  • W is N-R 6
  • R 6 is hydrogen
  • L is -(CH 2 ) m -X-(CH 2 ) n -, wherein m is O and n is O or 1 and X is O.
  • R 1 is adamantyl (ii) optionally substituted with -S(O) 2 -N(R 32 R 33 ), R 2 is hydrogen, R 3 and R 4 are each alkyl, R 5 is heteroaryl optionally substituted with halogen or haloalkyl, W is N-CN, and L is -(CH 2 ) m -X-(CH 2 ) n -, wherein m is O and n is O, and X is O.
  • R 1 is adamantyl (ii) optionally substituted with -CO 2 R wherein R is alkyl, R is hydrogen, R and R are each alkyl, R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, haloalkoxy, methoxy or haloalkyl, W is N-CN, and L is -(CH2) m -X-(CH2) n -, wherein m and n are each 0 and X is O.
  • R 1 is adamantyl (ii) optionally substituted with -CO 2 R 18 wherein R 18 is alkyl, R 2 is hydrogen, R 3 and R 4 are each alkyl, R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl, W is N-CN, and L is -(CH2) m -X-(CH2) n -, wherein m and n are each O and X is O.
  • R 1 is adamantyl (ii) optionally substituted with -CO2R 18 wherein R 18 is alkyl, R 2 is hydrogen, R 3 and R 4 are each alkyl, R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl, W is N-CN, and L is -(CH2) m -X-(CH2) n -, wherein m is 0 and n is 1 and X is O.
  • R 1 is adamantyl (ii) optionally substituted with -CO2R wherein R is alkyl, R is hydrogen, R and R are each alkyl, R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl, W is S, and L is -(CH 2 ) m -X-(CH 2 ) n -, wherein m is O and n is 1 and X is O.
  • R 1 is adamantyl (ii) optionally substituted with -CO2R 18 wherein R 18 is alkyl, R 2 is hydrogen, R 3 and R 4 are each alkyl, R 5 is heterocycle optionally substituted with heteroaryl that is optionally substituted with haloalkyl, W is S, and L is -(CH 2 ) n -, wherein n is 0.
  • R 1 is adamantyl (ii) optionally substituted with -CO2R 18 wherein R 18 is hydrogen, R 2 is hydrogen, R 3 and R 4 are each alkyl, R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl, W is N-CN, and L is -(CH 2 ) m -X-(CH 2 ) n -, wherein m is 0 and n is 1 and X is O.
  • R 1 is adamantyl (ii) optionally substituted with -CO2R 18 wherein R 18 is alkyl, R 2 is hydrogen, R 3 and R 4 are each alkyl, R 5 is heterocycle, W is N-CN, and L is -(CH 2 ) n -, wherein n is 0.
  • R 1 is adamantyl (ii) optionally substituted with -C(O)-N(R 19 R 20 ),
  • R 2 is hydrogen
  • R 3 and R 4 are each alkyl
  • R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl
  • W is N-CN
  • L is -(CH 2 ) m -X-(CH 2 ) n -, wherein m is 0 and n is 0 or 1 and X is O.
  • R 1 is adamantyl (ii) optionally substituted with -C(O)-N(R 19 R 20 ),
  • R 2 is hydrogen
  • R 3 and R 4 are each alkyl
  • R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl
  • W is N-R 6
  • R 6 is hydrogen
  • L is -(CH 2 ) m -X-(CH 2 ) n -, wherein m is 0 and n is 0 or 1 and X is O.
  • R 1 is adamantyl (ii) optionally substituted with -C(O)-N(R 19 R 20 ),
  • R 2 is hydrogen
  • R 3 and R 4 are each alkyl
  • R 5 is heteroaryl optionally substituted with halogen or haloalkyl
  • W is N-CN
  • L is -(CH2)m-X-(CH 2 )n-, wherein m is O and n is O or 1 and X is O.
  • Another embodiment is a compound of formula (I), wherein R 1 is adamantyl (ii) optionally substituted with cyano, R 2 is hydrogen, R 3 and R 4 are each alkyl, R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl, W is N-CN, and L is -(CH 2 ) m -X-(CH2)n-, wherein m is 0 and n is 0, and X is O.
  • Another embodiment is a compound of formula (I), wherein R 1 is adamantyl (ii) optionally substituted with cyano, R 2 is hydrogen, R 3 and R 4 are each alkyl, R 5 is heteroaryl optionally substituted with halogen or haloalkyl, W is N-CN, and L is -(CH 2 ) m -X-(CH2)n-, wherein m is 0 and n is 0, and X is O.
  • R 1 is adamantyl (ii) optionally substituted with cyano
  • R 2 is hydrogen
  • R 3 and R 4 are each alkyl
  • R 5 is heteroaryl optionally substituted with halogen or haloalkyl
  • W is N-CN
  • L is -(CH 2 ) m -X-(CH2)n-, wherein m is 0 and n is 0, and X is O.
  • R 1 is adamantyl (i)
  • R 2 is hydrogen
  • R 3 and R 4 are each alkyl
  • R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl
  • W is N-CN
  • L is -(CH 2 ) m -X-(CH2)n-, wherein m is 0 and n is 0, and X is O.
  • R 1 is bicyclo[2.2.2]octanyl (vi) optionally substituted with -CO 2 R 18 wherein R 18 is hydrogen or alkyl, R 2 is hydrogen, R 3 and R 4 are each alkyl, R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl, W is N-CN, and L is -(CH 2 )m-X-(CH 2 )n-, wherein m is 0 and n is 0, and X is O.
  • R 1 is bicyclo[2.2.2]octanyl (vi) optionally substituted with -C(O)-N(R 19 R 20 ),
  • R 2 is hydrogen
  • R 3 and R 4 are each alkyl
  • R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl
  • W is N-CN
  • L is -(CH 2 )m-X-(CH 2 )n-, wherein m is 0 and n is 0, and X is O.
  • R 1 is bicyclo[2.2.2]octanyl (vi) optionally substituted with cyano
  • R 2 is hydrogen
  • R 3 and R 4 are each alkyl
  • R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl
  • W is N-CN
  • L is -(CH 2 ) m -X-(CH2)n-, wherein m is 0 and n is 0, and X is O.
  • R 1 is bicyclo[2.2.2]octanyl (vi) optionally substituted with -OR 15 wherein R 15 is hydrogen, alkyl or haloalkyl, R 2 is hydrogen, R 3 and R 4 are each alkyl, R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl, W is N- CN, and L is -(CH 2 ) m -X-(CH 2 ) n -, wherein m is 0 and n is 0, and X is O.
  • R 1 is bicyclo[2.2.2]octanyl (vi) optionally substituted with -CHF 2
  • R 2 is hydrogen
  • R 3 and R 4 are each alkyl
  • R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl
  • W is N-CN
  • L is -(CH 2 ) m -X-(CH 2 ) n -, wherein m is 0 and n is 0, and X is O.
  • R 1 is cyclooctanyl (v)
  • R 2 is hydrogen
  • R 3 and R 4 are each methyl
  • R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl
  • W is N-CN
  • L is -(CH 2 )m-X-(CH 2 )n-, wherein m and n are both 0 and X is O.
  • R 1 is exo- bicyclo[2.2.1]heptyl (xvi)
  • R 2 is hydrogen
  • R 3 and R 4 are each methyl
  • R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl
  • W is N-CN
  • L is -(CH 2 ) m -X-(CH 2 ) n -, wherein m and n are both 0 and X is O.
  • R 1 is octahydro-2,5- methanopentalenyl (xvii)
  • R 2 is hydrogen
  • R 3 and R 4 are each methyl
  • R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl
  • W is N-CN
  • L is -(CH 2 ) m -X-(CH 2 ) n -, wherein m and n are both 0 and X is O.
  • R 1 is 1- azabicyclo[2.2.2]octyl (xvii)
  • R 2 is hydrogen
  • R 3 and R 4 are each methyl
  • R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl
  • W is N-CN
  • L is -(CH 2 ) m -X-(CH 2 ) n -, wherein m and n are both 0 and X is O.
  • R 1 is bicyclo[2.2.1]heptane- (viii) optionally substituted with -C(O)-N(R 19 R 20 ),
  • R 2 is hydrogen
  • R 3 and R 4 are each alkyl
  • R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl
  • W is N-CN
  • L is -(CH2)m-X-(CH 2 )n-, wherein m is 0 and n is 0, and X is O.
  • R 1 is bicyclo[2.2.1]heptane- (viii) optionally substituted with cyano
  • R 2 is hydrogen
  • R 3 and R 4 are each alkyl
  • R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl
  • W is N-CN
  • L is -(CH2) m -X-(CH2) n -, wherein m is 0 and n is 0, and X is O.
  • R 1 is bicyclo[2.2.1]heptane- (viii) optionally substituted with -CHF 2
  • R 2 is hydrogen
  • R 3 and R 4 are each alkyl
  • R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl
  • W is N-CN
  • L is -(CH 2 )Oi-X-(CH 2 )I 1 -, wherein m is 0 and n is 0, and X is O.
  • R 1 is bicyclo[2.2.1]heptane- (viii) optionally substituted with -OH
  • R 2 is hydrogen
  • R 3 and R 4 are each alkyl
  • R 5 is phenyl optionally substituted with 1 or 2 substituents independently selected from halogen, cyano, methoxy or haloalkyl
  • W is N-CN
  • L is -(CH 2 ) m -X-(CH 2 ) n -, wherein m is 0 and n is 0, and X is O.
  • Exemplary compounds of various embodiments include, but are not limited to: (l£)-2-(2-chloro-4-fluorophenoxy)- ⁇ /'-cyano-N-[(E)-5-hydroxy-2-adamantyl]-2- methylpropanimidamide;
  • stereoisomers Compounds of the invention may exist as stereoisomers wherein, asymmetric or chiral centers are present. These stereoisomers are “R” or “5"' depending on the configuration of substituents around the chiral element.
  • the terms “R” and “5"' used herein are configurations as defined in IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem., 1976, 45: 13-30.
  • the invention contemplates various stereoisomers and mixtures thereof and are specifically included within the scope of this invention.
  • Stereoisomers include enantiomers and diastereomers, and mixtures of enantiomers or diastereomers.
  • Individual stereoisomers of compounds of the invention may be prepared synthetically from commercially available starting materials which contain asymmetric or chiral centers or by preparation of racemic mixtures followed by resolution well-known to those of ordinary skill in the art.
  • Compounds of the invention can exist in isotope-labeled or -enriched form containing one or more atoms having an atomic mass or mass number different from the atomic mass or mass number most abundantly found in nature.
  • Isotopes can be radioactive or nonradioactive isotopes.
  • Isotopes of atoms such as hydrogen, carbon, phosphorous, sulfur, fluorine, chlorine, and iodine include, but are not limited to, 2 H, 3 H, 13 C, 14 C, 15 N, 18 0, 32 P, 35 S, 18 F, 36 Cl, and 125 I.
  • Compounds that contain other isotopes of these and/or other atoms are within the scope of this invention.
  • the isotope-labeled compounds contain deuterium ( 2 H), tritium ( 3 H) or 14 C isotopes.
  • Isotope-labeled compounds of this invention can be prepared by the general methods well known to persons having ordinary skill in the art. Such isotope- labeled compounds can be conveniently prepared by carrying out the procedures disclosed in the Examples disclosed herein and Schemes by substituting a readily available isotope- labeled reagent for a non-labeled reagent.
  • compounds may be treated with isotope-labeled reagents to exchange a normal atom with its isotope, for example, hydrogen for deuterium can be exchanged by the action of a deuteric acid such as D2SO4/D2O.
  • a deuteric acid such as D2SO4/D2O.
  • the isotope-labeled compounds of the invention may be used as standards to determine the effectiveness of 11- ⁇ -HSDl inhibitors in binding assays.
  • Isotope containing compounds have been used in pharmaceutical research to investigate the in vivo metabolic fate of the compounds by evaluation of the mechanism of action and metabolic pathway of the nonisotope-labeled parent compound (Blake et al. J. Pharm. Sci. 64, 3, 367-391 (1975)).
  • Such metabolic studies are important in the design of safe, effective therapeutic drugs, either because the in vivo active compound administered to the patient or because the metabolites produced from the parent compound prove to be toxic or carcinogenic (Foster et al.,
  • non-radio active isotope containing drugs such as deuterated drugs called “heavy drugs”
  • Increasing the amount of an isotope present in a compound above its natural abundance is called enrichment.
  • Examples of the amount of enrichment include from about 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 21, 25, 29, 33, 37, 42, 46, 50, 54, 58, 63, 67, 71, 75, 79, 84, 88, 92, 96, to about 100 mol %.
  • Stable isotope labeling of a drug can alter its physico-chemical properties such as pKa and lipid solubility. These effects and alterations can affect the pharmacodynamic response of the drug molecule if the isotopic substitution affects a region involved in a ligand-receptor interaction. While some of the physical properties of a stable isotope-labeled molecule are different from those of the unlabeled one, the chemical and biological properties are the same, with one important exception: because of the increased mass of the heavy isotope, any bond involving the heavy isotope and another atom will be stronger than the same bond between the light isotope and that atom. Accordingly, the incorporation of an isotope at a site of metabolism or enzymatic transformation will slow said reactions potentially altering the pharmcokinetic profile or efficacy relative to the non-istopic compound. Amides, Esters and Prodrugs
  • Prodrugs are derivatives of an active drug designed to ameliorate some identified, undesirable physical or biological property.
  • the physical properties are usually solubility (too much or not enough lipid or aqueous solubility) or stability related, while problematic biological properties include too rapid metabolism or poor bioavailability which itself may be related to a physicochemical property.
  • Prodrugs are usually prepared by: a) formation of ester, hemi esters, carbonate esters, nitrate esters, amides, hydroxamic acids, carbamates, imines, Mannich bases, and enamines of the active drug, b) functionalizing the drug with azo, glycoside, peptide, and ether functional groups, c) use of polymers, salts, complexes, phosphoramides, acetals, hemiacetals, and ketal forms of the drug.
  • a) formation of ester, hemi esters, carbonate esters, nitrate esters, amides, hydroxamic acids, carbamates, imines, Mannich bases, and enamines of the active drug b) functionalizing the drug with azo, glycoside, peptide, and ether functional groups
  • c) use of polymers, salts, complexes, phosphoramides, acetals, hemiacetals, and ketal forms of the drug for
  • Esters can be prepared from substrates of formula (I) containing either a hydroxyl group or a carboxy group by general methods known to persons skilled in the art. The typical reactions of these compounds are substitutions replacing one of the heteroatoms by another atom, for example:
  • Amides can be prepared from substrates of formula (I) containing either an amino group or a carboxy group in similar fashion. Esters can also react with amines or ammonia to form amides. Scheme 2
  • Another way to make amides from compounds of formula (I) is to heat carboxylic acids and amines together. O heat O
  • R and R' are independently substrates of formula (I), alkyl or hydrogen.
  • Various embodiments of formula (I) that are substrates for prodrugs and esters include, but not limited to, Examples 1, 2, 3, 4, 5, 6, 7, 8, 15, 22, 23, 24, 26, 30, 46, 49, 51, 55, 58, 80, 87, and 91.
  • Examples 11, 16, 17, 21, 28, 29, 48, and 63 are representative of esters of the invention.
  • Examples 14, 25, 31, 47, 50, 70, 74, 75, 76, 81, 82, and 88 are representative of amides of the invention.
  • the invention also provides pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula (I) in combination with a pharmaceutically acceptable carrier.
  • the pharmaceutical compositions of this invention can be administered to humans and other mammals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments or drops), bucally or as an oral or nasal spray.
  • compositions for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions and sterile powders for reconstitution into sterile injectable solutions or dispersions.
  • suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol, and the like, and suitable mixtures thereof), vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate, or suitable mixtures thereof.
  • Suitable fluidity of the composition may be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
  • compositions can also contain adjuvants such as preservative agents, wetting agents, emulsifying agents, and dispersing agents.
  • adjuvants such as preservative agents, wetting agents, emulsifying agents, and dispersing agents.
  • Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It also can be desirable to include isotonic agents, for example, sugars, sodium chloride and the like.
  • Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.
  • a parenterally administered drug form can be administered by dissolving or suspending the drug in an oil vehicle.
  • Suspensions in addition to the active compounds, can contain suspending agents, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, tragacanth, and mixtures thereof.
  • suspending agents for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, tragacanth, and mixtures thereof.
  • the compounds of the invention can be incorporated into slow-release or targeted-delivery systems such as polymer matrices, liposomes, and microspheres.
  • Injectable depot forms are made by forming microencapsulated matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations also are prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.
  • the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.
  • sterile injectable aqueous or oleaginous suspensions can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation also can be a sterile injectable solution, suspension or emulsion in a nontoxic, parenterally acceptable diluent or solvent such as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that can be employed are water, Ringer's solution, U. S. P. and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid are used in the preparation of injectables.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • one or more compounds of the invention is mixed with at least one inert pharmaceutically acceptable carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and salicylic acid; b) binders such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia; c) humectants such as glycerol; d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; e) solution retarding agents such as paraffin; f) absorption accelerators such as quaternary ammonium compounds; g) wetting agents such as cetyl alcohol and glycerol monostearate; h
  • compositions of a similar type may also be employed as fillers in soft and hard- filled gelatin capsules using lactose or milk sugar as well as high molecular weight polyethylene glycols.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well-known in the pharmaceutical formulating art. They can optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or in a certain part of the intestinal tract in a delayed manner. Examples of materials useful for delaying release of the active agent can include polymeric substances and waxes.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsif ⁇ ers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
  • a desired compound of the invention is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
  • Ophthalmic formulation, eardrops, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.
  • the ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • Powders and sprays can contain, in addition to the compounds of this invention, lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
  • Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.
  • liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes may be used.
  • the present compositions in liposome form may contain, in addition to the compounds of the invention, stabilizers, preservatives, and the like.
  • lipids are the natural and synthetic phospholipids and phosphatidylcholines (lecithins) used separately or together.
  • Dosage forms for topical administration of a compound of this invention include powders, sprays, ointments and inhalants.
  • the active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers or propellants.
  • Ophthalmic formulations, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.
  • Aqueous liquid compositions of the invention also are particularly useful.
  • compositions for rectal or vaginal administration are suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • suitable non-irritating carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • compositions comprise an effective amount of a compound of the invention formulated with one or more therapeutically suitable excipients.
  • therapeutically suitable excipients include, but are not limited to, sugars, cellulose and derivatives thereof, oils, glycols, solutions, buffers, colorants, releasing agents, coating agents, sweetening agents, flavoring agents, perfuming agents, and the like.
  • the effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration, the condition being treated and the severity of the condition being treated. Such dosage may be ascertained readily by a person skilled in the art.
  • a daily dosage of from about 0.1 milligram to about 100 milligram per kilogram of animal body weight, preferably given as a single daily dose or in divided doses two to six times a day, or in sustained release form.
  • the total daily dosage is from about 1.0 milligrams to about 1000 milligrams, preferably from about 1 milligram to about 50 milligrams. In the case of a 70 kg adult human, the total daily dose will generally be from about 7 milligrams to about 350 milligrams. This dosage regimen may be adjusted to provide the optimal therapeutic response.
  • Glucocorticoids are steroid hormones that play an important role in regulating multiple physiological processes in a wide range of tissues and organs.
  • glucocorticoids are potent regulators of glucose and lipid metabolism. Excess glucocorticoid action may lead to insulin resistance, type-2 diabetes, dyslipidemia, visceral obesity and hypertension.
  • Cortisol and cortisone are the major active and inactive forms of glucocorticoids in humans, respectively, while corticosterone and dehydrocorticosterone are the major active and inactive forms in rodents.
  • Glucocorticoid action is initiated by the binding of glucocorticoids to receptors, such as glucocorticoid receptors and mineralocorticoid receptors.
  • receptors such as glucocorticoid receptors and mineralocorticoid receptors.
  • the main mineralocorticoid aldosterone controls the water and electrolyte balance in the body.
  • the mineralocorticoid receptors have a high affinity for both Cortisol and aldosterone.
  • Cortisol is an important and well-recognized anti-inflammatory agent (J. Baxer, Pharmac. Ther., 2,605-659 (1976)), if present in large amount, it also has detrimental effects. For example, Cortisol antagonizes the effects of insulin in the liver resulting in reduced insulin sensitivity and increased gluconeogenesis. Therefore, patients who already have impaired glucose tolerance have a greater probability of developing type 2 diabetes in the presence of abnormally high levels of Cortisol. Since glucocorticoids are potent regulators of glucose and lipid metabolism, excessive glucocorticoid action may lead to insulin resistance, type 2 diabetes, dyslipidemia, visceral obesity and hypertension.
  • the present invention relates to the administration of a therapeutically effective dose of an 1 l ⁇ -HSDl inhibitor for the treatment, control, amelioration, and/or delay of onset of diseases and conditions that are mediated by excess or uncontrolled, amounts or activity of Cortisol and/or other corticosteroids.
  • Inhibition of the 1 l ⁇ -HSDl enzyme limits the conversion of inactive cortisone to active Cortisol.
  • Cortisol may cause, or contribute to, the symptoms of these diseases and conditions if it is present in excessive amounts.
  • Dysregulation of glucocorticoid activity has been linked to metabolic disorders, including type 2 diabetes, metabolic syndrome, Cushing's Syndrome, Addison's Disease, and others.
  • Glucocorticoids upregulate key glucoeneogenic enzymes in the liver such as phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase), and therefore lowering local glucocorticoid levels in this tissue is expected to improve glucose metabolism in type 2 diabetics.
  • PEPCK phosphoenolpyruvate carboxykinase
  • G6Pase glucose-6-phosphatase
  • mice 11 ⁇ -HSDl receptor whole-body knockout mice, and mice overexpressing 1 l ⁇ -HSD2 in fat (resulting in lower levels of active glucocorticoid in fat) have better glucose control than their wild type counterparts (Masuzaki, et al., Science, 294, 2166-2170 (2001); Harris, et al., Endocrinology, 142, 114-120 (2001); Kershaw et al., Diabetes, 54, 1023-1031 (2005)). Therefore, specific 1 l ⁇ -HSDl inhibitors could be used for the treatment or prevention of type 2 diabetes and/or insulin resistance.
  • compounds of this invention may also have utility in the treatment and prevention of the numerous conditions that often accompany type 2 diabetes and insulin resistance, including the metabolic syndrome, obesity, reactive hypoglycemia, and diabetic dyslipidemia.
  • the following diseases, disorders and conditions are related to type 2 diabetes, and some or all of these may be treated, controlled, prevented and/or have their onset delayed, by treatment with the compounds of this invention: hyperglycemia, low glucose tolerance, insulin resistance, obesity, lipid disorders, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL levels, high LDL levels, atherosclerosis and its sequelae, vascular restenosis, pancreatitis, abdominal obesity, neurodegenerative disease, retinopathy, nephropathy, neuropathy, metabolic syndrome and other disorders where insulin resistance is a component.
  • Abdominal obesity is closely associated with glucose intolerance (Montaque et al., Diabetes, 49, 883-888 (2000)), hyperinsulinemia, hypertriglyceridemia, and other factors of metabolic syndrome (also known as Syndrome X), such as high blood pressure, elevated LDL, and reduced HDL.
  • metabolic syndrome also known as Syndrome X
  • Animal data supporting the role of HSDl in the pathogenesis of the metabolic syndrome is extensive (Masuzaki, et al, Science, 294, 2166-2170 (2001); Paterson et al, Proc Natl. Acad. ScL USA, 101, 7088-93, (2004); Montague et al., Diabetes, 49, 883-888 (2000)).
  • administering may be useful in the treatment or control of the metabolic syndrome.
  • administration of an 11 ⁇ -HSD 1 inhibitor may be useful in the treatment or control of obesity by controlling excess Cortisol, independent of its effectiveness in treating or prophylactically treating NIDDM.
  • Long-term treatment with an 11 ⁇ -HSD 1 inhibitor may also be useful in delaying the onset of obesity, or perhaps preventing it entirely if the patients use an 11 ⁇ - HSDl inhibitor in combination with controlled diet and exercise.
  • Potent, selective 11 ⁇ - HSDl inhibitors should also have therapeutic value in the treatment of the glucocorticoid- related effects characterizing the metabolic syndrome, or any of the following related conditions: hyperglycemia, low glucose tolerance, insulin resistance, obesity, lipid disorders, dyslipidemia, hyperlipidemia, hypertriglycidemia, hypercholesterolemia, low HDL levels, high LDL levels, atherosclerosis, vascular restenosis, pancreatitis, obesity, neurodegenerative disease, retinopathy, nephropathy, hepatic steatosis or related liver diseases, and Syndrome X, and other disorders where insulin resistance is a component.
  • 11 ⁇ -HSD 1 is expressed in pancreatic islet cells, where active glucocorticoids have a negative effect on glucose stimulated insulin secretion (Davani et al., Biol. Chem., 10, 34841- 34844 (2000); Tadayyon et al, Expert Opin. Investig. Drugs, 12, 307-324 (2003); Billaudel et al, J. Endocrinol, 95, 315-20 (1982)). It has been reported that the conversion of dehydrocorticosterone to corticosterone by 11 ⁇ -HSD 1 inhibits insulin secretion from isolated murine pancreatic beta cells.
  • Glucocorticoids may bind to and activate glucocorticoid receptors (and possibly mineralocorticoid receptors) to potentiate the vasoconstrictive effects of both catecholamines and angiotensin II (Pirpiris et al., Hypertension, 19, 567-574 (1992); Kornel et al., Steroids, 58, 580-587 (1993): Walker et al, Clin. Sd., 82, 597-605 (1992)).
  • the 1 l ⁇ -HSDl enzyme is present in vascular smooth muscle, which is believed to control the contractile response together with 1 l ⁇ -HSD2.
  • Cushing's syndrome is a life-threatening metabolic disorder characterized by chronically elevated glucocorticoid levels caused by either excessive endogenous production of Cortisol from the adrenal glands, or by the administration of high doses of exogenous glucocorticoids, such as prednisone or dexamethasone, as part of an anti-inflammatory treatment regimen.
  • Typical Cushingoid characteristics include central obesity, diabetes and/or insulin resistance, dyslipidemia, hypertension, reduced cognitive capacity, dementia, osteoporosis, atherosclerosis, moon faces, buffalo hump, skin thinning, and sleep deprivation among others (Principles and Practice of Endocrinology and Metabolism. Edited by Kenneth Becker, Lippincott Williams and Wilkins Publishers, Philadelphia, 723-8 (2001)). It is therefore expected that potent, selective 1 l ⁇ -HSDl inhibitors would be effective for the treatment of Cushing's disease.
  • 1 l ⁇ -HSDl inhibitors may be effective in the treatment of many features of the metabolic syndrome including hypertension and dyslipidemia.
  • the combination of hypertension and dyslipidemia contribute to the development of atherosclerosis, and therefore it would be expected that administration of a therapeutically effective amount of an 1 l ⁇ -HSDl inhibitor would treat, control, delay the onset of, and/or prevent atherosclerosis and other metabolic syndrome-derived cardiovascular diseases.
  • NPE nonpigmented epithelial cells
  • glucocorticoid activity shifts the immune response to a humoral response, when in fact a cell based response may be more beneficial to the patients. Inhibition of 1 l ⁇ -HSDl activity may reduce glucocorticoid levels, thereby shifting the immune response to a cell based response.
  • 1 l ⁇ -HSDl specific inhibitors could be used for the treatment of tuberculosis, psoriasis, stress in general, and diseases or conditions where high glucocorticoid activity shifts the immune response to a humoral response.
  • Glucocorticoids are known to cause a variety of skin related side effects including skin thinning, and impairment of wound healing (Anstead, Adv Wound Care, 11, 277-85 (1998); Beer et al, Vitam Horm., 59, 217-39 (2000)).
  • 1 l ⁇ -HSDl is expressed in human skin fibroblasts, and it has been shown that the topical treatment with the non-selective 1 l ⁇ -HSDl and 1 l ⁇ -HSD2 inhibitor glycerrhetinic acid increases the potency of topically applied hydrocortisone in a skin vasoconstrictor assay (Hammami, et al., J. Clin. Endocrinol. Metab., 73, 326-34 (1991)).
  • Advantageous effects of selective 1 l ⁇ -HSDl inhibitors on wound healing have also been published (International Publication No. WO 2004/11310). It is therefore expected that potent, selective 1 l ⁇ -HSDl inhibitors would treat wound healing or skin thinning due to excessive glucocorticoid activity.
  • glucocorticoids decrease bone mineral density and increase fracture risk. This effect is mainly mediated by inhibition of osteoblastic bone formation, which results in a net bone loss (Kim et al., J. Endocrinol., 162, 371-379 (1999); Bellows et al., Bone, 23, 119-125 (1998); Cooper et al., Bone, 27, 375-381 (2000)).
  • Glucocorticoids are also known to increase bone resorption and reduce bone formation in mammals (Turner et al., Calcif. Tissue Int., 54, 311-5 (1995); Lane et al., Med. Pediatr. Oncol., 41, 212-6 (2003)).
  • Glucocorticoids such as prednisone and dexamethasone are also commonly used to treat a variety of inflammatory conditions including arthritis, inflammatory bowel disease, and asthma. These steroidal agents have been shown to increase expression of 1 l ⁇ -HSDl mRNA and activity in human osteoblasts (Cooper et al., J. Bone Miner. Res., 17, 979-986 (2002)). Similar results have been shown in primary osteoblast cells and MG-63 osteosarcoma cells where the inflammatory cytokines TNF alpha and IL-I ⁇ increase 1 l ⁇ -HSDl mRNA expression and activity (Cooper et al, J. Bone Miner. Res., 16, 1037-1044 (2001)).
  • glucocorticoid-induced acute psychosis exemplifies a more pharmacological induction of this response, and is of major concern to physicians when treating patients with these steroidal agents (Wolkowitz et al., Ann NYAcadSci., 1032, 191-4 (2004)).
  • Thekkapat et al. have recently shown that 1 l ⁇ - HSDl mRNA is expressed in human hippocampus, frontal cortex and cerebellum, and that treatment of elderly diabetic individuals with the non-selective 1 l ⁇ -HSDl and 1 l ⁇ -HSD2 inhibitor carbenoxolone improved verbal fluency and memory (Thekkapat et al., Proc Natl Acad Sd USA.
  • the CNS diseases, disorders and conditions can be treated, controlled, prevented or delayed, by treatment with the compounds of this invention.
  • Administration of a therapeutic dose of an 1 l ⁇ -HSDl inhibitor may reduce, ameliorate, control and/or prevent disorders such as stress in general, neurodegeneration, the cognitive impairment associated with aging, neuronal dysfunction, dementia, steroid-induced acute psychosis, decline in cognitive function in Alzheimer's and associated dementias, cognitive deficits associated with aging and neurodegeneration, dementia, senile dementia, AIDS dementia, depression, major depressive disorder, psychotic depression, treatment resistant depression, anxiety, panic disorder, post traumatic stress disorder, decline in cognitive function in Cushing's syndrome, depression in Cushing's syndrome, steroid-induced acute psychosis, cognitive deficits associated with diabetes, attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), mild cognitive impairment, steroid-induced acute psychosis and schizophrenia.
  • ADHD attention deficit hyperactivity disorder
  • an embodiment is a method of inhibiting 1 l ⁇ -HSDl, comprising administering to a mammal, a therapeutically effective amount of a compound of formula (I).
  • Another embodiment is treating or prophylactically treating the above disorders in a mammal.
  • the disorders may be mediated by excessive glucocorticoid action in a mammal.
  • Another embodiment is a method of treating disorders including, but are not limited to, Cushing's syndrome, non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders (dyslipidemia), metabolic syndrome, hyperglycemia, low glucose tolerance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL levels, high LDL levels, atherosclerosis and its sequelae, vascular restensosis, pancreatitis, abdominal obesity, retinopathy, nephropather, neuropathy, hypertension, other disorders where insulin resistance is a component, glaucoma, arthritis, osteoporosis, neuronal dysfunction, neurodegeneration, cognitive impairment associated with aging, dementia, Alzheimer's disease, decline in cognitive function in Alzheimer's disease and associated dementias, cognitive deficits associated with aging and neurodegeneration, dementia, senile dementia, AIDS dementia, anxiety, panic disorder, post traumatic stress disorder, steroid-induced acute psychosis, cognitive deficits associated with diabetes, attention deficit disorder in general, attention
  • Another embodiment provides a method for treating Alzheimer's disease in a subject such that signs and symptoms are reduced.
  • the method comprises administering to the subject in need of treatment thereof (e.g., a mammal, such as a human) a therapeutically effective amount of any of the compounds as described herein, or a pharmaceutically acceptable salt thereof.
  • the method comprises administering to the subject a therapeutically effective amount of any of the compounds as described herein, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of at least one cognitive enhancing drug.
  • a "cognitive enhancing drug” is a drug that improves impaired human cognitive abilities of the brain (namely, thinking, learning, and memory).
  • Cognitive enhancing drugs work by altering the availability of neurochemicals (e.g., neurotransmitters, enzymes, and hormones), by improving oxygen supply, by stimulating nerve growth, or by inhibiting nerve damage.
  • Examples of cognitive enhancing drugs include a compound that increases the activity of acetylcholine such as, but not limited to, an acetylcholine receptor agonist (e.g., a nicotinic ⁇ -7 receptor agonist or allosteric modulator, an ⁇ 4 ⁇ 2 nicotinic receptor agonist or allosteric modulators), an acetylcholinesterase inhibitor (e.g., donepezil, rivastigmine, and galantamine), a butyrylcholinesterase inhibitor, an N-methyl-D-aspartate (NMDA) receptor antagonist (e.g., memantine), an activity-dependent neuroprotective protein (ADNP) agonist, a serotonin 5- HTlA receptor agonist (e.g., xalipro
  • cognitivo drugs include, but are not limited to, cholinesterase inhibitors such as donepezil (Aricept ® ), rivastigmine (Exelon ® ), galanthamine (Reminyl ® ), N-methyl-D-aspartate antagonists such as memantine (Namenda ® ).
  • cholinesterase inhibitors such as donepezil (Aricept ® ), rivastigmine (Exelon ® ), galanthamine (Reminyl ® ), N-methyl-D-aspartate antagonists such as memantine (Namenda ® ).
  • At least one cognitive enhancing drug can be administered simultaneously with the compounds of the present invention or sequentially with the compounds of the present invention (and in any order). Additionally, it is believed that the combinations described herein may have additive or synergistic effects when used in the above-described treatment.
  • the present invention relates to a method for preventing (the development of) a disease condition, such as a neurodegeneration disorder or a neuropsychiatric disorder.
  • a disease condition such as a neurodegenerative disorder or a neuropsychiatric disorder by administration of any of the compounds described herein means that the detectable physical characteristics or symptoms of the disease or condition do not develop following the administration of the compound described herein.
  • the method of the present invention comprises administering to the subject in need of treatment thereof (e.g., a mammal, such as a human) a therapeutically effective amount of any of the compounds as described herein, or a pharmaceutically acceptable salt thereof.
  • the method comprises administering to the subject a therapeutically effective amount of any of the compounds as described herein, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of at least one cognitive enhancing drug.
  • the present invention relates to a method for preventing the progression (e.g., worsening) of a disease condition, such as a neurodegeneration disorder or a neuropsychiatric disorder.
  • the method comprises administering to the subject in need of treatment thereof (e.g., a mammal, such as a human) a therapeutically effective amount of any of the compounds as described herein, or a pharmaceutically acceptable salt thereof.
  • the method comprises administering to the subject a therapeutically effective amount of any of the compounds as described herein, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of at least one cognitive enhancing drug.
  • biomarkers, diagnostic tests or combination of biomarkers and diagnostic tests known to those skilled the art can be used to determine whether or not (1) a subject is at risk of developing one or more of neurodegeneration disorders or neuropsychiatric disorders; or (2) the neurodegeneration disorders or neuropsychiatric disorders in the subject previously diagnosed with one or more of the aforementioned disorders is progressing (e.g., worsening).
  • Another embodiment provides methods for determining whether an 1 l ⁇ -HSDl inhibitor is effective at treating a subject in need thereof. Such methods may be used to determine the efficacy of an 1 l ⁇ -HSDl inhibitor, including those which are unknown or unconfirmed to have such efficacy.
  • compounds of formulas (4-4) and (4-5), wherein R 1 , R 2 , R 3 , R 4 , R 5 , and L are as defined in the Summary of the Invention can be prepared from compounds of formula (4-1). Accordingly nitriles of formula (4-1) can be converted to the corresponding imidates of formula (4-2) upon treatment with HCl in a solvent such as ethanol. Further exemplification of the preparation of compounds of formula (4-2) can be found in U.S. patent application Pub. No. US2006/0025614. Compounds of formula (4-2) can then be treated with cyanamide in either ethanol or phosphate buffer to supply compounds of formula (4-3).
  • compounds of formulas (4-4), (5-3), and (5-4), wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and L are as defined in the Summary of the Invention can be prepared from compounds of formula (5-1).
  • Compounds of formula (5-1) can be prepared as described in Sorensen et al., Bioorg. Med. Chem. Lett. 17, 527-532 (2007). Additionally, preparation of compounds of formula (5-1) are described in U.S. Patent Nos. 7,528,282; 7,511,175; 7,435,833 and 7,217,838; U. S. application publication Nos.
  • 2007118185 WO 2007111921, WO 2007145834, WO 2007145835, WO 2008088540, WO 2008011453, WO 2008099145, WO 2008012532, WO 2008053194, WO 2008024892, WO 2008074384, WO 2008052638, WO 2007124337, WO 2007127765, WO 2007127726, WO 2007127693, WO 2007127704, WO 2007127688, WO 2007127901, WO 2007127763, WO 2007124329, WO 2007124254, WO 2007107470, WO 2007101270, WO 2008069313, WO 2007084314, WO 2008157752, WO 2008142859, WO 2008006703, WO 2008006702, WO 2007107550, WO 2007115935, WO 2007051810, WO 2007051811, WO 2008110196, WO 2007144394, WO 2008134221, WO 2008127924, WO 2006048750, WO 2007
  • compounds of formula (6-5) wherein R 1 , R 2 , R 3 , R 4 , R 5 , L and W are as defined in the Summary of the Invention can be prepared from compounds of formula (6-1).
  • Compounds of formula (6-1), wherein LG is a leaving group such as chlorine, bromine, iodine, trifluoromethanesulfonate, or/?-toluenesulfonate can be treated with H-L-R 5 , wherein L is O or S, in the presence of a base such as cesium carbonate in an optionally heated solvent such as ⁇ /, ⁇ /-dimethylformamide to give compounds of formula (6-2).
  • a base such as cesium carbonate
  • an optionally heated solvent such as ⁇ /, ⁇ /-dimethylformamide
  • compound (7-7) can be prepared from compound (7-1).
  • Compound (7-1) can be transformed in two steps to compound (7-2). Initially the amine is protected, in this instance, benzyloxycarbonyl is shown. Then the ester is hydrolyzed by methodology known in the art.
  • Compound (7-2) is treated as described in Tetrahedron Lett., 43, 8687-8691 (2002) to give compound (7-3).
  • Compound (7-3) can then be hydrolyzed to give compound (7-4).
  • Compound (7-4) can then be converted in three steps to compound (7- 5) (Bioorg. Med. Chem. Lett., 17, 527-532 (2002)). In the first step, the tertiary alcohol is sulfonylated.
  • compound (8-4) can be prepared from compound (8-1).
  • Compound (8-1) is prepared as described in Scheme 7 when the acetate moiety is removed from compound (7-5).
  • Compound (8-1) can be methylated with methyl iodide in the presence of base to give compound (8-2).
  • Compound (8-1) can be oxidized with sodium perborate to give sulfone, (8-3). Removal of the amine protecting group using methods known in the art give compound (8-4).
  • Compound (8-4) is representative of (R X )(R 2 )NH and can be used in Schemes 4 and 6.
  • Compound (9-1) can be prepared as described in Wilcox et ah, J. Org. Chem., 29, 2209-2211 (1964). Compound (9-1) can then be converted to compound (9-2) by the procedures described in Wilcox et al., J. Org. Chem., 33, 877-880 (1968). Compound (9-2) can then be converted to compound (9-3) upon treatment with ammonia. Alternatively, compound (9-2) can be transformed to compounds of formulas (9-4) and (9-6) using the methodologies described in Scheme 7. Also, using the methodologies in Scheme 8 convert compound (9-2) into compound (9-5). Compounds (9-3), (9-4), (9-5), and (9-6) are representative of (R 1 )(R 2 )NH and can be used in Schemes 4 and 6.
  • compounds of formulas (5-3), (4-4), and (5-4) can be prepared from compounds of formula (5-2).
  • Compounds of formula (5-2) can be treated with triethyloxonium tetrafluoroborate in a solvent such as heated dichloromethane to give compounds of formula (10-1).
  • Compounds of formula (10-1) can then be treated as described in Scheme 5 to give compounds of formulas (5-3), (4-4), and (5-4).
  • Compounds of formulas (5-3), (4-4), and (5-4) are representative of compounds of formula (I).
  • compounds of formula (11-2) and (11-4) can be prepared from compounds of formula (11-1).
  • Compounds of (11-1), wherein v is 1 or 2, R" is alkyl, and P is a nitrogen protecting group can be converted to compounds of formula (11-2) by removal of said protecting group.
  • One skilled in the art will match the deprotecting reaction conditions to the protecting group used. For example, when P is benzyloxycarbonyl, hydrogenation in the presence of a palladium catalyst will affect removal of P.
  • Compounds of (11-1) can also be reduced to the corresponding alcohols of formula (11-3).
  • the ester moiety of compounds of formula (11-1) can be reduced using such reagents as borane-tetrahydrofuran complex to give the hydroxymethyl group found in compounds of (11-3).
  • Compounds of formula (11-3) can be oxidized with reagents such as the Dess-Martin periodinane to produce an intermediate aldehyde. Subsequent treatment with (diethylamino)sulfur trifluoride (DAST) converts the aldehyde to a difluoromethyl moiety. Removal of the protecting group, P, under appropriate reaction conditions delivers compounds of formula (11-4).
  • DAST diethylamino)sulfur trifluoride
  • compounds of formula (11-1) can also be converted to compounds of formulas (12-3) and (12-4).
  • Compounds of formula (11-2), wherein v is 1 or 2, R" is alkyl, and P is a nitrogen protecting group can be converted to compounds of formula (12-1) by hydrolysis of the ester moiety.
  • Compounds of formula (12-1) can be converted to the corresponding acid chloride by treatment with a reagent such as oxalyl chloride. The intermediate acid chloride can then be reacted with ammonia to give carboxamides of formula (12-2). Removal of the protecting group under conditions known to one skilled in the art supplies compounds of formula (12-3).
  • Compounds of formula ((12-2) can also be dehydrated with reagents such as trifluoroacetic anhydride to convert the carboxamide moiety to a cyano group. Removal of the protecting group supplies compounds of formula (12-4).
  • Compounds of formulas (12-2) and (12-4) are representative of (R X )(R 2 )NH and can be used in Schemes 4 and 6.
  • compounds of formula (13-1), wherein R" is alkyl and v is 1 or 2 can be converted to compounds of formula (13-3). Accordingly, compounds of formula (13-1) can be treated under Hunsdiecker reaction conditions to convert the carboxylic acid moiety to the corresponding bromide. Subsequent exposure to hydroxide transforms the bromide to the corresponding alcohol and also hydrolyzes the ester to the carboxylic acids of formula (13-2). Curtius rearrangement of compounds of formula (13-2) by treatment with diphenyl phosphoryl azide in the presence of an alcohol such as t-butanol delivers the intermediate t-butylcarbamate.
  • nitrogen protecting groups can be used for protecting amine groups during the synthesis of compounds of formula (I). Such methods, and some suitable nitrogen protecting groups, are described in Greene and Wuts (Protective Groups In Organic Synthesis, Wiley and Sons, 1999).
  • suitable nitrogen protecting groups include, but are not limited to, te/t-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), benzyl (Bn), acetyl, and trifluoracetyl. More particularly, the Boc protecting group may be removed by treatment with an acid such as trifluoroacetic acid or hydrochloric acid.
  • the Cbz and Bn protecting groups may be removed by catalytic hydrogenation and acetyl and trifluoracetyl protecting groups may be removed by variety of conditions including the use of sodium, potassium or lithium hydroxide in aqueous organic or alcoholic solvents.
  • the compounds and intermediates of the invention may be isolated and purified by methods well-known to those skilled in the art of organic synthesis.
  • Examples of conventional methods for isolating and purifying compounds can include, but are not limited to, chromatography on solid supports such as silica gel, alumina, or silica derivatized with alkylsilane groups, by recrystallization at high or low temperature with an optional pretreatment with activated carbon, thin-layer chromatography, distillation at various pressures, sublimation under vacuum, and trituration, as described for instance in "Vogel's Textbook of Practical Organic Chemistry", 5th edition (1989), by Furniss et ah, pub. Longman Scientific & Technical, Essex CM20 2JE, England.
  • Some compounds of the invention have at least one basic site whereby the compound can be treated with an acid to form a desired salt.
  • a compound may be reacted with an acid at or above room temperature to provide the desired salt, which is deposited, and collected by filtration after cooling.
  • acids suitable for the reaction include, but are not limited to tartaric acid, lactic acid, succinic acid, as well as mandelic acid, atrolactic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, naphthalenesulfonic acid, carbonic acid, fumaric acid, gluconic acid, acetic acid, propionic acid, salicylic acid, hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, citric acid, or hydroxybutyric acid, camphorsulfonic acid, malic acid, phenylacetic acid, aspartic acid, glutamic acid, and the like.
  • the invention contemplates pharmaceutically active compounds either chemically synthesized or formed by in vivo biotransformation to compounds of formula (I).
  • the titled compound was prepared from 4-(methoxycarbonyl)bicyclo[2.2.1]heptane- 1 -carboxylic acid (BAI-5) using the methodology using the methodology used to prepare BAI-6.
  • the titled compound was prepared from methyl 4-
  • BAI-7 ⁇ [(benzyloxy)carbonyl]amino ⁇ bicyclo[2.2.1]heptane-l-carboxylate (BAI-7) using the methodology described for the preparation of BA-2.
  • LCMS (ESI+) m/z 170.1 (M+H) + .
  • BAI-7 ⁇ [(benzyloxy)carbonyl]amino ⁇ bicyclo[2.2.1]heptane-l-carboxylate (BAI-7) using the methodology described for the preparation of BAI- 13.
  • 1 H NMR 400 MHz, CDCl 3 ) ⁇ ppm 7.31-7.36 (m, 5H), 5.06 (s, 2H), 3.64 (s, 2H), 1.92-1.93 (m, 2H), 1.67-1.78 (m, 4H), 1.43 (s, 2H), 1.38-1.41 (m, 2H); LCMS (ESI+) m/z 275.1 (M+H) + .
  • the titled compound was prepared from benzyl (4-formylbicyclo[2.2.1]hept-l- yl)carbamate (BAI-16) using the methodology described for the preparation of BAI-17.
  • the titled compound was prepared from benzyl (4-carbamoylbicyclo[2.2.1]hept-l- yl)carbamate (BAI-11) using the methodology described for the preparation of BA-6.
  • 1 H NMR 400 MHz, DMSO-J 6 ) ⁇ ppm 6.96 (s, IH), 6.74 (s, IH), 1.76-1.83 (m, 2H), 1.50-1.55 (m, 4H), 1.44 (s, 2H), 1.40-1.42 (m, 2H); LCMS(ESI+) m/z 155.1 (M+H) + .
  • Methyl 4-bromobicyclo[2.2.2]octane-l-carboxylate (BAI- 19, 0.246 g, 0.001 mol) was refluxed in 25 mL of 1 % sodium hydroxide solution for 24 hours. After cooling, the reaction solution was acidified with 6 N hydrochloric acid and extracted with ether (50 mL> ⁇ 6). The combined ether layers were dried over magnesium sulfate and concentrated to small volume. Recrystallization from n-hexane and diethyl ether (40: 10 mL) gave the titled compound.
  • 1 H NMR 400 MHz, DMSO-J 6 ) ⁇ ppm 1. 1.68-1.78 (m, 6H), 1.48-1.52 (m, 6H), 4.00 (s, IH), 12.00 (s, IH).
  • Step E ethyl ⁇ /-cyano-2-methyl-2-phenoxypropanimidoate
  • the titled compound was synthesized according to the methods described by Sorensen et al, Bioorg. Med. Chem. Lett. 2007, 17, 527-532.
  • Example IA To a solution of Example IA (0.76 g, 2 mmol) in toluene (25 mL) was added Lawesson's reagent (0.81 g, 2 mmol) and then the reaction mixture was heated at 80 0 C for 4 hours. The reaction mixture was concentrated under reduced pressure, and the residue was partitioned between saturated aqueous NaHCO 3 and ethyl acetate. The organic layers were combined, dried (MgSO 4 ), filtered and concentrated. The residue was purified by flash chromatography (SiO 2 , 0-40% ethyl acetate in hexanes) to provide the titled compound. MS (DCI + ) mlz 398 (M+H) + .
  • Example IB A solution of Example IB (0.46 g, 2.0 mmol) in acetonitrile (20 mL) was treated with cyanamide (0.12 g, 2.9 mmol), mercury(II) acetate (0.56 g, 1.7 mmol), and triethylamine
  • Example 3 A To a solution of Example 3 A (2.5 g, 9.1 mmol) in acetonitrile (7 mL) was added a solution of sodium phosphate monobasic monohydrate (5.0 g, 36.5 mmol), sodium phosphate dibasic heptahydrate (4.9 g, 18.2 mmol), and cyanamide (0.8 g, 18.2 mmol) in water (70.0 mL). The reaction mixture was stirred at room temperature for 72 hours, and then the mixture was extracted with methylene chloride (3 ⁇ 30 mL). The combined organic extracts were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure to obtain the titled compound. MS (ESI + ) mlz 263 (M+H) + .
  • Example 3 C l-(4-Chlorophenyl)- ⁇ /'-cyano-N-[(E)-5-hydroxy-2-adamantyl]cyclobutanecarboximidamide
  • reaction mixture was then cooled, dissolved in dichloromethane (2 mL) and purified by column chromatography using an Analogix® Intelliflash 280TM (SiO 2 , 0- 100% of ethyl acetate in dichloromethane) to afford the titled compound.
  • Example 4B Ethyl N-cyano-2-(2,4-difluorophenyl)acetimidate To a solution of Example 4 A (7.0 g, 29.7 mmol) in ethanol (100 mL) was added a solution of cyanamide (1.25 g, 29.7 mmol) in diethyl ether (25 mL). The reaction mixture was stirred at room temperature for 3 days. The reaction mixture was then filtered and the filtrate was concentrated to obtain the titled compound. MS (ESI + ) mlz 225 (M+H) + .
  • Example 3C The titled compound was synthesized according to the procedure described in Example 3C substituting Example 3B with ethyl ⁇ /-cyano-2-(2-fluorophenyl)acetimidate (U.S. patent application Pub. No. US2006/0025614).
  • Example 6A and cyanamide (Aldrich) were processed using the method described for Example 4B to obtain the titled compound.
  • Example 7A and cyanamide (Aldrich) were processed using the method described for Example 4B to obtain the titled compound.
  • Example 8A and cyanamide (Aldrich) were processed using the method described for Example 3B to obtain the titled compound. MS (ESI + ) mlz 267 (M+H) + . Alternative Preparation of Example 8B
  • Example 8B was also prepared following the procedures described for the preparation of ethyl ⁇ /-cyano-2-methyl-2-phenoxypropanimidoate (CI-I) substituting 4-chlorophenol for phenol.
  • Example 9A 2-(4-Chlorophenoxy)-2-methyl- ⁇ /-[(E)-5-(methylsulfonyl)-2-adamantyl]propanamide
  • the titled compound was synthesized according to the methods described in Sorensen et al, Bioorg. Med. Chem. Lett, 2007, 17, 527-532.
  • Example 8B and (£)-4-aminoadamantane-l -sulfonamide were processed using the method described for Example 2 to obtain the titled compound.
  • Example 8B and Example 1 IA were processed using the method described for Example 2 to obtain the titled compound.
  • the titled compound was synthesized according to the methods described in Sorensen et al, Bioorg. Med. Chem. Lett., 2007, 17, 527-532.
  • Example 9 A solution of Example 9 (200 mg, 0.45 mmol) in acetonitrile (20 mL) was treated with 0-methylhydroxylamine hydrochloride (94 mg, 1.1 mmol), mercury(II) acetate (216 mg, 0.67 mmol) and triethylamine (0.12 mL, 0.90 mmol). The reaction mixture was heated at 80 0 C for 18 hours. The mixture was then concentrated under reduced pressure and the residue was partitioned between saturated aqueous NaHCO 3 and ethyl acetate. The combined organic layers were dried (MgSO 4 ), filtered and concentrated. The residue was purified by chromatography (hexane-ethyl acetate, 1 :2) to afford the titled compound.
  • Example 11 To a solution of Example 11 (0.48 g, 1.1 mmol) in tetrahydrofuran (2 mL), methanol (4 mL) and water (4 mL) was added 5 N aqueous NaOH (1.1 mL, 5.6 mmol). After stirring at room temperature for 16 hours, the reaction mixture was concentrated to half the volume, the pH was adjusted to ⁇ 5, and the mixture was extracted with ethyl acetate (3> ⁇ 15 mL). The combined organic extracts were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure to obtain the titled compound in crude form which was used without additional purification. MS (ESI + ) mlz 416 (M+H) + .
  • Example 14A To a solution of Example 14A (0.37 g, 0.9 mmol) in dichloromethane (10 mL) were added 1-hydroxy-benzotriazole hydrate (0.16 g, 1.1 mmol), 7V-(3-dimethylaminopropyl)-N- ethylcarbodiimide hydrochloride (0.25 g, 1.3 mmol) and 30% aqueous ammonium hydroxide (1.0 mg, 8.9 mmol). The reaction mixture was stirred at room temperature for 16 hours and then quenched with water (1OmL). The aqueous layer was extracted with dichloromethane (3 ⁇ 20 mL). The combined organic extracts were dried over anhydrous Na 2 SO 4 , filtered and concentrated.
  • Example 15C Lithium hydroxide monohydrate (1.7 g, 40.3 mmol) was added to a suspension of Example 15A (4.7 g, 13.4 mmol) in tetrahydrofuran (320 mL) and water (160 mL) at room temperature. The reaction mixture was stirred at 55 0 C overnight. The reaction was concentrated under reduced pressure to remove tetrahydrofuran, acidified to pH ⁇ 3 by adding aqueous 1 MHCl while cooling. The precipitate was collected by filtration and dried in a dessicator containing KOH overnight. Recrystallization from heptane afforded the titled compound. MS (ESI + ) m/z 227 (M+H) + .
  • Example 15C Lithium hydroxide monohydrate (1.7 g, 40.3 mmol) was added to a suspension of Example 15A (4.7 g, 13.4 mmol) in tetrahydrofuran (320 mL) and water (160 mL) at room temperature.
  • Example IB The titled compound was synthesized according to the procedures described in Example IB and Example 1C substituting Example IA with Example 15B.
  • the titled compound was synthesized according to the methods described in Sorensen et al, Bioorg. Med. Chem. Lett., 2007, 17, 527-532.
  • Example 21 A Methyl (E)-4- [(2-methyl-2- ⁇ 4- [5 -(trifluoromethyl)pyridin-2-yl]piperazin- 1 -yl ⁇ propanoyl) amino] adamantane- 1 -carboxylate
  • Example 22A 3-(4-Chlorophenyl)-2,2-dimethylpropanenitrile
  • a solution of lithium dusopropylamide (11.0 mL, 21.9 mmol, 2 M in tetrahydrofuran, Aldrich) in tetrahydr ⁇ furan (100 mL) was added isobutyronitrile (2.0 mL, 21.9 mmol) at 0-5 °C.
  • a solution of l-(bromomethyl)-4- chlorobenzene (3.0 g, 14.6 mmol) in tetrahydrofuran (10 ml.) was added at the same temperature.
  • Example 4A to obtain the titled compound. MS (ESI + ) mlz 240 (M+H) + .
  • Example 22C 3-(4-Chlorophenyl)- ⁇ /-[(E)-5-hydroxy-2-adamantyl]-2,2-dimethylpropanimidamide
  • reaction mixture was cooled, dissolved in dichlorormethane (2 mL) and purified by preparative HPLC on a on a Phenomenex® Luna® C8(2) 5 urn IOOA AXIATM column (30mmx75mm) using a gradient of 20% to 95% acetonitrile in 10 mM of ammonium acetate over 10 minutes at a flow rate of 50 niL/minute to provide the titled compound.
  • Example 22A and cyanamide (Aldrich) were processed using the method described for Example 3B to obtain the titled compound.
  • Example 17 A solution of Example 17 (0.35 g, 0.7 mmol) in methanol :tetrahydrofuran (1 :1, 10 mL) was treated with 2 NNaOH (0.5 mL, 3.5 mmol) and stirred for 30 hours. The reaction mixture was concentrated in vacuo, diluted with water, acidified to pH ⁇ 5 and then extracted with ethyl acetate. The organic layer was washed with brine, dried (MgSO 4 ) and concentrated to give the titled compound.
  • Example 24 A solution of Example 24 (0.34 g, 0.72 mmol) in CH 2 Cl 2 (20 mL) was treated with lH-benzo[d][l,2,3]triazol-l-ol hydrate (0.12 g, 0.8 mmol) followed by N 1 - ((ethylimino)methylene)-N 3 ,N 3 -dimethylpropane-l,3-diamine hydrochloride (0.17 g, 0.91 mmol) and the reaction mixture was stirred for 1 hour. Then 30% aqueous NH 4 OH (0.5 mL, 3.6 mmol) was added, and the reaction mixture was stirred for 18 hours at room temperature.
  • lH-benzo[d][l,2,3]triazol-l-ol hydrate (0.12 g, 0.8 mmol
  • Example 28A To a solution of Example 28A (2.1g, 5 mmol) in tetrahydrofuran (25 mL) was added Lawesson reagent (2.04 mg, 5 mmol) and the reaction mixture was heated at 50 0 C for 4 hours. The reaction mixture was concentrated under reduced pressure and the residue was partitioned between saturated NaHCO 3 and ethyl acetate. The combined organic layers were dried (MgSO 4 ), filtered and concentrated. The residue was purified by flash chromatography (SiO 2 , 0-40 % ethyl acetate in hexanes) to provide the titled compound. MS (DCI+) m/z 432 (M+H) + .
  • Example 1C substituting Example IB with Example 28B.
  • Example 21 (366 mg, 0.7 mmol) in dichloromethane (8 mL) was treated with a 1 molar solution of triethyloxonium tetrafluoroborate in dichloromethane (1 mL, 1 mmol). The reaction mixture was stirred at 45 0 C for 18 hours. The reaction mixture was concentrated in vacuo, and the residue was dissolved in ethanol and then treated with cyanamide (120 mg, 2.8 mmol) and triethylamine (0.3 mL, 2.2 mmol). The reaction mixture was heated at 80 0 C for 18 hours and then concentrated in vacuo. The residue was partitioned between ethyl acetate and water.
  • Example 30 (E)-4-[((lE)-N-Cyano-2-methyl-2- ⁇ 4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-l- yl ⁇ propanimidoyl)amino] adamantane- 1 -carboxylic acid
  • the titled compound was synthesized according to the procedure described in Example 14A substituting Example 11 with Example 29.
  • Example 32A 6-( ⁇ 4,4-Dimethyl- 1 - [(E)S -(methylsulfonyl)-2-adamantyl] -5 -oxopyrrolidin-3 - yl ⁇ methoxy)nicotinonitrile
  • the titled compound was synthesized according to the methods described in reference: Yeh et al, Bioorg. Med. Chem. Lett. 2006, 16, 5555-5560.
  • Example 32B 6-( ⁇ 4,4-Dimethyl-l-[(E)-5-(methylsulfonyl)-2-adamantyl]-5-thioxopyrrolidin-3- yl ⁇ methoxy)nicotinonitrile
  • Example IB The titled compound was synthesized according to the procedures described in Example IB substituting Example IA with (S)-l-(3-chloro-2-methylphenylsulfonyl)-iV- cyclohexylpiperidine-3-carboxamide.
  • Example 34 To a solution of Example 34 (200 mg, 0.48 mmol) in dichloromethane (15 mL) was added triethyloxonium tetrafluoroborate (0.96 mL, 0.96 mmol, 1 M in dichloromethane) and the mixture was stirred at room temperature for overnight. The reaction mixture was then heated to 50 0 C for 3 more days with continued stirring. The reaction mixture was cooled, concentrated and triturated in ether. The obtained product was dissolved in ethanol (2 mL) and cyanamide (61 mg, 1.4mmol) and triethylamine (0.2 mL, 1.4 mmol) were added.
  • Example 14A An alternative preparation of Example 14A is herein described.
  • a solution of Example 14B 50 mg, 0.12 mmol) in 1,4-dioxane (0.5 mL) was added 5 M hydrogen chloride in water (0.5 mL, 2.5 mmol). After stirring at 60 0 C for 6 hours, the reaction mixture was cooled, diluted with water (5 mL) and extracted with ethyl acetate (2 x 10 mL). The combined organic extracts were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • Example 3C The titled compound was synthesized according to the procedure described in Example 3C substituting £-2-amino-5-hydroxyadamantane and Example 3B with E-A- Amino-adamantane-1-carbonitrile (International Publication No. WO 2007/118185, filed October 18, 2007) and Example 8B, respectively.
  • the residue was purified by preparative HPLC on a Phenomenex® Luna® C8(2) 5 um 100 A AXIATM column (30mm x 75mm) .with a gradient of 10-95% (acetonitrile/0.1% trifluoroacetic acid in water) at a flow rate of 50mL/min for 10 minutes to obtain the title compound.
  • the titled compound was synthesized according to the procedure described in Example 39 substituting l-azatricyclo[3.3.1.1 3 ' 7 )decan-4s-amine dihydrochloride with quinuclidin-3 -amine dihydrochloride (Aldrich).
  • Example 44C (lE)- ⁇ /'-cyano-2-(2-fluorophenoxy)-2-methyl- ⁇ /-[(E)-5-(methylsulfonyl)adamantan-2- yl]propanimidamide
  • Example IB The titled compound was synthesized according to the methods described in Example IB substituting Example IA with Example 45 A.
  • Example 1C The titled compound was synthesized according to the methods described in Example 1C substituting Example IB with Example 45B.
  • Example 46A methyl 4- ⁇ [2-(4-chlorophenoxy)-iV-cyano-2- methylpropanimidoyl]amino ⁇ bicyclo [2.2.2]octane- 1 -carboxylate
  • Example 8B and methyl 4-aminobicyclo[2.2.2]octane-l -carboxylate obtained by aqueous bicarbonate wash of 4-methoxycarbonyl-bicyclo[2.2.2]oct-l-yl ammonium chloride salt, Prime Organics
  • LCMS (ESI + ) mlz 404 (M+H) + .
  • Example 46B 4- ⁇ [2-(4-chlorophenoxy)-N-cyano-2-methylpropanimidoyl]amino ⁇ bicyclo[2.2.2]octane-l- carboxylic acid
  • the titled compound was synthesized according to the procedures described in
  • Example 14A substituting Example 11 with Example 46A.
  • 1 H NMR 300 MHz, DMSO-J 6 ) ⁇ ppm 1.62 (s, 6 H), 1.72 - 1.88 (m, 6 H), 1.90 - 2.06 (m, 6 H), 6.92 - 7.01 (m, 2 H), 7.25 (s, 1 H), 7.34 - 7.42 (m, 2 H), 12.09 (s, 1 H); MS (ESI + ) mlz 391 (M+H) + .
  • Example 47 4- ⁇ [2-(4-chlorophenoxy)-N-cyano-2-methylpropanimidoyl] amino ⁇ bicyclo [2.2.2]octane- 1 - carboxamide
  • Example 14B The titled compound was synthesized according to the procedures described in Example 14B substituting Example 14A with Example 46B.
  • 1 H NMR 300 MHz, DMSO-J 6 ) ⁇ ppm 1.62 (s, 6 H), 1.69 - 1.83 (m, 6 H), 1.89 - 2.05 (m, 6 H), 6.73 (s, 1 H), 6.92 - 7.01 (m, 2 H), 6.95 (s, 1 H), 7.24 (s, 1 H), 7.33 - 7.44 (m, 2 H); MS (ESI + ) mlz 390 (M+H) + .
  • Example 47 was also prepared using the procedure described in Example 85 substituting 4-aminobicyclo[2.2.2]octane-l -carboxamide (BA-6) for 4- (difluoromethyl)bicyclo[2.2.2]octan- 1 -amine (BA-4).
  • Example 8B (524 mg, 2 mmol) and 4-aminobicyclo[2.2.2]octane-l-carbonitrile (BA-
  • Example 48A To a solution of Example 48A (0.44 g, 1.4 mmol) in methanol (4 mL) and water (4 mL) was added 5 N aqueous NaOH solution (1.4 mL, 7.1 mmol). After stirring at 60 0 C for 16 hours, the reaction mixture was cooled, neutralized to pH ⁇ 7 with 3 NHCl, and concentrated to obtain crude 2-[(15',5i?,6S)-6-(4-chlorophenyl)-3-azabicyclo[3.2.0]hept-3-yl]- 2-methylpropanoic acid.
  • Example 48D methyl (E)-4-( ⁇ (lE)-2-[(li?*,5 l S*,6i?*)-6-(4-chlorophenyl)-3-azabicyclo[3.2.0]hept-3-yl]-N- cyano-2-methylpropanimidoyl ⁇ amino)adamantane- 1 -carboxylate
  • triethyloxonium tetrafluoroborate 1.5 mL, 1.5 mmol, 1 M in methylene chloride, Aldrich
  • the reaction mixture was then concentrated under reduced pressure and triturated in ether.
  • the obtained precipitate was dissolved in ethanol (2 mL) and cyanamide (60 mg, 1.5 mmol) and triethylamine (0.2 m l, 1.5 mmol) were added.
  • the reaction mixture was cooled, concentrated under reduced pressure and diluted with water (10 mL).
  • the aqueous layer was extracted with ethyl acetate (3 ⁇ 10 mL).
  • the combined organic extracts were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • Example 8 To a solution of Example 8 (50 mg, 0.13 mmol) in methanol (2 mL) were added ammonium formate (81 mg, 1.3 mmol) and 10% Pd/C (2 mg) under an inert atmosphere. The reaction mixtures was stirred at room temperature for 2 hours, filtered and concentrated under reduced pressure. The residue was purified by preparative HPLC on a Phenomenex® Luna® C8(2) 5 ⁇ m IOOA AXIATM column (30mmx75mm) using a gradient of 20% to 95% acetonitrile in 10 mM of ammonium acetate over 10 minutes at a flow rate of 50 niL/minute to provide the titled compound.
  • Example 51A To a solution of Example 51A (0.9 g, 4.0 mmol) in methylene chloride (10 mL) and triethylamine (2.2 mL, 15.8 mmol) was added 2,2,2-trifluoroacetic anhydride (1.6 mL, 11.9 mmol) at 0 0 C. The reaction mixture was allowed to warm to room temperature and stirred for three hours before methanol was added to quench the reaction. The reaction mixture was washed with saturated aqueous NaHCO 3 solution, dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • Example 5 IB Through a cooled solution of Example 5 IB (6.5 g, 33 mmol) and ethanol (9.6 mL, 165 mmol) in methylene chloride (10 ml) was bubbled HCl gas at 0 0 C for 30 minutes. The reaction was kept in a refrigerator at 4 0 C for 60 hours. The reaction mixture was then concentrated and triturated with diethyl ether to obtain a precipitate of the titled compound. MS (ESI + ) ml z 244 (M+H) + .
  • Example 5 ID ethyl N-cyano-2-(2,4-difluorophenoxy)-2-methylpropanimidate
  • Example 51C and cyanamide (Aldrich) were processed using the method described for Example 3B to obtain the titled compound.
  • Example 3C substituting Example 3B with Example 5 ID.
  • Example 3C The titled compound was synthesized according to the procedure described in Example 3C substituting £-2-amino-5-hydroxyadamantane and Example 3B with E-A- aminoadamantane-1-carbonitrile (International Publication No. WO 2007/118185, filed October 18, 2007) and Example 5 ID, respectively.
  • Example 53 A ethyl 2-(4-chloro-2-fluorophenoxy)-2-methylpropanoate A mixture of 4-chloro-2-fluorophenol (11.28Og, 77 mmol), ethyl 2-bromoisobutyrate
  • Example 53 A (18 g, 70 mmol) in a mixture of tetrahydrofuran (100 mL) and water (50 mL) was treated with LiOH (4.96 g, 207 mmol). The reaction mixture was stirred at 55 0 C overnight and then concentrated under reduced pressure to remove tetrahydrofuran. The basic aqueous layer was extracted with ethyl acetate (2x100 mL) to extract out the unreacted starting phenol. The aqueous layer was acidified to pH ⁇ 3, extracted with ethyl acetate (2x200 mL). The combined organic layers were washed with brine, dried (MgSO 4 ) and concentrated. The crude product was used in the next step without additional purification. MS (DCI+) m/z 233 (M+H) + .
  • Example 53C To a solution of Example 53C (8 g, 34.5 mmol) in dichloromethane (100 mL) and triethylamine (19.25 mL, 138 mmol) was added trifluoroacetic anhydride (slow addition, 14.63 mL, 104 mmol) at 0 0 C. After the addition, the solution was allowed to warm to room temperature and stirred for 2 hours before methanol (20 mL) was added to quench the reaction. The solution was washed with saturated NaHCO 3 solution, dried (Na 2 SO 4 ), and concentrated.
  • Example 53E ethyl 2-(4-chloro-2-fluorophenoxy)-2-methylpropanimidoate hydrochloride Through a cooled solution of Example 53D (7.2 g, 33.7 mmol) in ethanol (75 mL) and dichloromethane (30 mL) was bubbled HCl gas at 0 0 C for 30 minutes. The reaction was kept in a refrigerator for 24-72 hours (checked by LCMS). The reaction mixture was then concentrated and the residue was triturated with diethyl ether. The titled compound was collected by filtration.
  • Example 53F ethyl 2-(4-chloro-2-fluorophenoxy)- ⁇ /-cyano-2-methylpropanimidoate
  • acetonitrile 15 mL
  • the reaction mixture was stirred at room temperature for 55 hours and then extracted with dichloromethane (3 ⁇ 50 mL).
  • the combined organic extracts were dried (Na 2 SO 4 ), filtered and concentrated to give the titled compound.
  • Example 3C The titled compound was synthesized according to the methods described in Example 3C substituting Example 53F for Example 3B and E-4-aminoadamantane-l-carbonitrile (International Publication No. WO 2007/118185, filed October 18, 2007) for £-5-hydroxy-2- adamantamine.
  • Example 3C The titled compound was synthesized according to the methods described in Example 3C substituting Example 53F for Example 3B and (£)-4-aminoadamantane-l -sulfonamide (Sorensen, B., et al, Bioorg. Med. Chem. Lett., 2007, 17, 527-532) for £-5-hydroxy-2- adamantamine.
  • Example 3C The titled compound was synthesized according to the procedure described in Example 3C substituting £-2-amino-5-hydroxyadamantane and Example 3B with exo-2- aminonorbornane (Aldrich) and Example 5 ID, respectively.
  • Example 5 ID and (£)-4-aminoadamantane-l -sulfonamide were processed using the method described for Example 3C to obtain the titled compound.
  • Example 51A substituting 2-(2,4-difluorophenoxy)-2-methylpropanoic acid with 2-(5- chloropyridin-2-yloxy)-2-methylpropanoic acid. (Liu, P., et al., Journal of Medicinal Chemistry, 2007, 50,15, 3427-3430). MS (ESI + ) m/z 215 (M+H) + .
  • Example 58B
  • Example 58C ethyl 2-(5 -chloropyridin-2-yloxy)-2-methylpropanimidate hydrochloride
  • the titled compound was synthesized according to the procedure described in Example 51C substituting Example 5 IB with Example 58B.
  • Example 58D ethyl 2-(5-chloropyridin-2-yloxy)-N-cyano-2-methylpropanimidate
  • Example 58C and cyanamide (Aldrich) were processed using the method described for Example 3B to obtain the titled compound.
  • Example 3C The titled compound was synthesized according to the procedure described in Example 3C substituting £-2-amino-5-hydroxyadamantane and Example 3B with E-A- aminoadamantane-1-carbonitrile (International Publication No. WO 2007/118185, filed
  • Example 3C The titled compound was synthesized according to the methods described in Example 3C substituting Example 53F for Example 3B and methyl (£)-4-aminoadamantane-l- carboxylate (Becker, C.L., et al, Org. Process R & D, 2008, 12, 1114-1118) for E-5-hydroxy- 2-adamantamine.
  • Example 3C substituting £-2-amino-5-hydroxyadamantane and Example 3B with cyclooctanamine (Aldrich) and Example 5 ID, respectively.
  • Example 66 ⁇ /-(exo-bicyclo[2.2.1]hept-2-yl)-2-(4-chloro-2-fluorophenoxy)- ⁇ /'-cyano-2- methylpropanimidamide
  • the titled compound was synthesized according to the methods described in Example
  • Example 58D and (£)-4-aminoadamantane-l-sulfone were processed using the method described for Example 3C to obtain the titled compound.
  • Example 58D and (£)-4-aminoadamantane-l -sulfonamide were processed using the method described for Example 3C to obtain the titled compound.
  • Example 70 The titled compound was synthesized according to the procedure described in Example 38 substituting Example 8B with Example 5 ID, respectively.
  • Example 70 Example 70
  • Example 7OA methyl (E)-4- ⁇ [(benzyloxy)carbonyl] amino ⁇ adamantane- 1 -carboxylate
  • Benzyl chloroformate (6.9 mL, 48.8 mmol) was added drop wise to a stirred and cooled (0 0 C) solution of methyl (£)-4-aminoadamantane-l -carboxylate hydrochloride salt (Becker, C.L., et al, Org. Process R & D, 2008, 12, 1114-1118) (10.0 g, 40.7 mmol) and diisopropylethylamine (21.3 mL, 122 mmol) in dry methylene chloride (100 mL).
  • Example 7OC 1.0 g, 3.0 mmol
  • Pd(OH) 2 /C 0.2 g, 0.3 mmol
  • the reaction mixture was stirred at room temperature under H 2 atmosphere (balloon) for 4 hours.
  • the reaction mixture was then filtered through a pad of diatomaceous earth and concentrated under reduced pressure to provide the titled compound.
  • MS (ESI + ) m/z 195 (M+H) + .
  • Example 5 ID and Example 7OD were processed using the method described for Example 3C to obtain the titled compound.
  • Example 72 (IE)-N-(I -azabicyclo[2.2.2]oct-3-yl)-2-(4-chloro-2-fluorophenoxy)- ⁇ /'-cyano-2- methylpropanimidamide The titled compound was synthesized according to the methods described in Example
  • Example 73 2-(4-chloro-2-fluorophenoxy)- ⁇ /'-cyano-N-(hexahydro-2,5-methanopentalen-3a(lH)-yl)-2- methylpropanimidamide
  • the titled compound was synthesized according to the methods described in Example
  • Example 14 The titled compound was synthesized according to the methods described in Example 14 substituting Example 63 for Example 11.
  • Example 75 (£)-4-( ⁇ (l£)-2-[(5-chloropyridin-2-yl)oxy]-JV-cyano-2- methylpropanimidoyl ⁇ amino)adamantane- 1 -carboxamide
  • Example 58D and Example 7OD were processed using the method described for Example 3C to obtain the titled compound.
  • Example 50 1 H NMR (300 MHz, DMSO-J 6 ) ⁇ ppm 1.30 - 1.42 (m, 2 H), 1.50 (s, 6 H), 1.69 - 1.88 (m, 9 H), 1.93 - 2.13 (m, 2 H), 3.44 - 3.54 (m, 1 H), 6.66 (s, 1 H), 6.87 - 6.99 (m, 4 H), 7.17 - 7.27 (m, 2 H)); MS (ESI + ) m/z 356 (M+H) + .
  • Example 77 (lE)- ⁇ /'-cyano-2-methyl- ⁇ /-[(E)-5-(methylsulfonyl)adamantan-2-yl]-2-(pyridin-2- yloxy)propanimidamide
  • Example 53 A solution of Example 53 (50 mg, 0.111 mmol) in methanol (3mL) was treated with ammonium formate (70.1 mg, 1.111 mmol) and palladium 10% palladium on carbon (1.182 mg, 0.011 mmol). The reaction mixture was stirred at room temperature for 18 hours. The reaction mixture was filtered and concentrated. Purification by reverse phase HPLC method using a Phenomenex® Luna® C8, 5 ⁇ M IOOA AXIATM column (30 mm> ⁇ 75 mm) and a gradient of 10-100% acetonitrile and 10 mM ammonium acetate in water provided the titled compound.
  • Example 79 (lE)- ⁇ /'-cyano-2-(2-fluorophenoxy)-2-methyl- ⁇ /-[(E)-5-sulfamoyladamantan-2- yl]propanimidamide
  • the titled compound was synthesized according to the methods described in Example
  • Example 80 (lE)- ⁇ / I -cyano-2-(2-fluorophenoxy)- ⁇ /-[(E)-5-hydroxyadamantan-2-yl]-2- methylpropanimidamide
  • Example 84 ⁇ /'-cyano-N-(4-cyanobicyclo[2.2.2]oct-l-yl)-2-methyl-2-phenoxypropanimidamide To a solution of Example 82 (70 mg, 0.2 mmol) and triethylamine (120 mg, 1.2 mmol) in dichloromethane cooled in an ice bath was added trifluoroacetic anhydride (125 mg, 0.6 mmol) dropwise. After addition was complete, the mixture was stirred overnight at room temperature.
  • Example 8B 4-(Difluoromethyl)bicyclo[2.2.2]octan-l-amine (BA-4) and Example 8B were mixed, and the neat mixture was heated to 100 0 C under nitrogen and stirred for 3 hours. After cooling, the mixture was dissolved in a small amount of ethanol and purified by prep-HPLC [Waters 2767; Benetnach 10-Cl 8 20x250 mm, 10 ⁇ m; 35-85% acetonitrile/water (0.05% trifluoroacetic acid), 30 niL/minute; detection at 214 and 254 nm] to give the titled compound.
  • Example 85 The titled compound was prepared using the procedure described in Example 85 substituting ethyl ⁇ /-cyano-2-methyl-2-phenoxypropanimidoate (CI-I) for Example 8B. Purification was achieved by preparative reverse phase HPLC [Waters 2767; Benetnach 10- C18 20x250 mm, 10 ⁇ m; 58-78% acetonitrile/water (0.05% trifiuoroacetic acid), 30 niL/minute; detection at 214 and 254 nm].
  • Example 88 4- ⁇ [2-(4-chlorophenoxy)- ⁇ /-cyano-2-methylpropanimidoyl]amino ⁇ bicyclo[2.2.1]heptane-l- carboxamide
  • the titled compound was prepared using the procedure described in Example 85 substituting 4-aminobicyclo[2.2.1]heptane-l-carboxamide (BA-7) for 4- (difluoromethyl)bicyclo[2.2.2]octan-l -amine (BA-4).
  • Example 8B The titled compound was prepared using the procedure described in Example 85 substituting 4-(difluoromethyl)bicyclo[2.2.1]heptan-l-amine (BA-5) for 4- (difluoromethyl)bicyclo[2.2.2]octan-l -amine (BA-4) and ethyl iV-cyano-2-methyl-2- phenoxypropanimidoate (CI-I) for Example 8B.
  • Example 93A and cyanamide (Aldrich) were processed using the method described for Example 3B to obtain the titled compound.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • AIDS & HIV (AREA)

Abstract

La présente invention concerne des inhibiteurs de l'enzyme 11-β-hydroxystéroïde déshydrogénase de type 1 et leur utilisation dans le traitement du diabète non-insulinodépendant de type 2, de la résistance à l'insuline, de l'obésité, des troubles lipidiques, du syndrome métabolique, de troubles du système nerveux central et de maladies et états qui sont liés à un excès de glucocorticoïdes.
PCT/US2010/031660 2009-04-20 2010-04-20 Nouveaux dérivés amide et amidine et leurs utilisations WO2010123838A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MX2011011082A MX2011011082A (es) 2009-04-20 2010-04-20 Derivados de amida y amidina novedosos y usos de los mismos.
CN201080026472.4A CN102459158B (zh) 2009-04-20 2010-04-20 新的酰胺和脒衍生物和其用途
CA2757866A CA2757866A1 (fr) 2009-04-20 2010-04-20 Nouveaux derives amide et amidine et leurs utilisations
JP2012507294A JP5848698B2 (ja) 2009-04-20 2010-04-20 新規アミドおよびアミジン誘導体ならびにこれらの使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17094309P 2009-04-20 2009-04-20
US61/170,943 2009-04-20

Publications (2)

Publication Number Publication Date
WO2010123838A2 true WO2010123838A2 (fr) 2010-10-28
WO2010123838A3 WO2010123838A3 (fr) 2011-03-03

Family

ID=43011706

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/031660 WO2010123838A2 (fr) 2009-04-20 2010-04-20 Nouveaux dérivés amide et amidine et leurs utilisations

Country Status (5)

Country Link
JP (2) JP5848698B2 (fr)
CN (2) CN103772239B (fr)
CA (1) CA2757866A1 (fr)
MX (1) MX2011011082A (fr)
WO (1) WO2010123838A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5848698B2 (ja) * 2009-04-20 2016-01-27 アッヴィ・インコーポレイテッド 新規アミドおよびアミジン誘導体ならびにこれらの使用
EA201590696A1 (ru) * 2012-11-06 2015-08-31 Эли Лилли Энд Компани Новые бензилсульфонамидные соединения, подходящие в качестве ингибиторов mogat-2
CN104628673A (zh) * 2015-02-10 2015-05-20 佛山市赛维斯医药科技有限公司 一类含叔丁基脒结构的腈基苯噻唑羧酸酰胺类化合物及用途
CN104592150A (zh) * 2015-02-10 2015-05-06 佛山市赛维斯医药科技有限公司 一类含环丙基脒结构的腈基苯噻唑羧酸酰胺类化合物及用途
CN104672164A (zh) * 2015-02-10 2015-06-03 佛山市赛维斯医药科技有限公司 一类含苯基脒结构的sglt2/sglt1双靶点抑制剂、其制备方法及用途
CN104628672A (zh) * 2015-02-10 2015-05-20 佛山市赛维斯医药科技有限公司 一类含苯基脒结构的烷氧苯基噻唑羧酸酰胺类化合物及用途
CN104672165B (zh) * 2015-02-10 2016-06-01 佛山市赛维斯医药科技有限公司 一类含环丙基脒结构的烷氧苯基噻唑羧酸酰胺类双靶点抑制剂、其制备方法及用途
CN104592152A (zh) * 2015-02-10 2015-05-06 佛山市赛维斯医药科技有限公司 一种含脒结构的硝基苯基噻唑羧酸酰胺类双靶点抑制剂、其制备方法及用途
CN104910097A (zh) * 2015-02-10 2015-09-16 佛山市赛维斯医药科技有限公司 一类含苯基脒结构的卤代苯基噻唑羧酸酰胺类化合物、其制备方法及用途
CN104672166A (zh) * 2015-02-10 2015-06-03 佛山市赛维斯医药科技有限公司 一种含脒结构的腈基苯基噻唑羧酸酰胺类双靶点抑制剂、其制备方法及用途
CN104592148A (zh) * 2015-02-10 2015-05-06 佛山市赛维斯医药科技有限公司 一类含环丙基脒结构的硝基苯噻唑羧酸酰胺类化合物及用途
CN104710382A (zh) * 2015-02-10 2015-06-17 佛山市赛维斯医药科技有限公司 一类含叔丁基脒结构的卤代苯基噻唑羧酸酰胺类化合物及用途
CN104557766A (zh) * 2015-02-10 2015-04-29 佛山市赛维斯医药科技有限公司 一类含叔丁基脒结构的硝基苯噻唑羧酸酰胺类化合物及用途
CN110850012B (zh) * 2018-08-21 2022-07-08 四川弘远药业有限公司 一种1-(2,3-二氯苯基)哌嗪盐酸盐及其有关物质的检测方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0333522A2 (fr) * 1988-03-18 1989-09-20 MITSUI TOATSU CHEMICALS, Inc. Dérivés du catéchol et préparations pharmaceutiques les contenant
EP0418065A2 (fr) * 1989-09-12 1991-03-20 MITSUI TOATSU CHEMICALS, Inc. Dérivés de l'acide dihydrocaféique, leur usage pour des traitements médicaux et compositions pharmaceutiques les contenant
US5338745A (en) * 1990-08-10 1994-08-16 Mitsui Toatsu Chemicals, Incorporation Amide derivatives of dihydrocaffeic acid and their application to pharmaceuticals
WO2006024628A1 (fr) * 2004-08-30 2006-03-09 Janssen Pharmaceutica N.V. Derives de lactame tricyclique utilises en tant qu'inhibiteurs de 11-beta-hydroxysteroide deshydrogenase
US20060149070A1 (en) * 2005-01-05 2006-07-06 Rohde Jeffrey J Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2450386A (en) * 1945-09-04 1948-09-28 Boots Pure Drug Co Ltd Manufacture of compounds containing amidine groups
GB1306139A (fr) * 1970-08-06 1973-02-07
US4156014A (en) * 1977-03-21 1979-05-22 The Upjohn Company N-(2-aminocycloheptyl)alkanoylanilides and in the treatment of depression
FR2387977A1 (fr) * 1977-04-19 1978-11-17 Hoechst France Procede de fabrication de l'acide thienyl-2 acetique
JPS562957A (en) * 1979-06-18 1981-01-13 Otsuka Pharmaceut Factory Inc N-adamantylthioamide derivative
CA1157774A (fr) * 1980-07-30 1983-11-29 Anthony Cerami Methode pour diminuer la viscosite de la mucine
WO1992004054A1 (fr) * 1990-08-30 1992-03-19 STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITY, PORTLAND, OREGON, and THE UNIVERSITY OF OREGON, EUGENE, OREGON, Johnson Hall, University of Oregon Amidines substituees ayant une forte affinite avec le recepteur sigma et utilisations desdites amidines
DE19921886A1 (de) * 1999-05-12 2000-11-16 Bayer Ag Substituierte N-Cyano-amidine
JP2004521878A (ja) * 2000-12-07 2004-07-22 スィーヴィー　セラピューティクス　インコーポレイテッド Ａｂｃａ−１を上昇させる化合物
WO2004056744A1 (fr) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides utilises comme inhibiteurs de la hydroxysteroide deshydrogenase
CN1227010C (zh) * 2003-04-22 2005-11-16 中国药科大学 取代的四氢异喹啉衍生物的用途
US7880001B2 (en) * 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
WO2006024627A2 (fr) * 2004-08-30 2006-03-09 Janssen Pharmaceutica N.V. Derives d'acetamides n-2 adamantanyl-2-phenoxy utilises en tant qu'inhibiteurs de la deshydrogenase 11-beta hydroxysteroide
CN101137616A (zh) * 2005-01-05 2008-03-05 艾博特公司 11-β-羟甾类脱氢酶1型酶的抑制剂
ZA200800142B (en) * 2005-06-08 2009-05-27 Japan Tobacco Inc Heterocyclic compound
EP1801098A1 (fr) * 2005-12-16 2007-06-27 Merck Sante Dérivés de 2-Adamantylurea comme inhibiteurs de 11B-HSD1
EP1935420A1 (fr) * 2006-12-21 2008-06-25 Merck Sante Dérivés du 2-adamantyl-butyramide en tant qu'inhibiteurs selectifs de la 11beta-HSD1
JP2010526777A (ja) * 2007-04-24 2010-08-05 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー 置換アミドの医薬用途
JP5736098B2 (ja) * 2007-08-21 2015-06-17 アッヴィ・インコーポレイテッド 中枢神経系障害を治療するための医薬組成物
JP5848698B2 (ja) * 2009-04-20 2016-01-27 アッヴィ・インコーポレイテッド 新規アミドおよびアミジン誘導体ならびにこれらの使用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0333522A2 (fr) * 1988-03-18 1989-09-20 MITSUI TOATSU CHEMICALS, Inc. Dérivés du catéchol et préparations pharmaceutiques les contenant
EP0418065A2 (fr) * 1989-09-12 1991-03-20 MITSUI TOATSU CHEMICALS, Inc. Dérivés de l'acide dihydrocaféique, leur usage pour des traitements médicaux et compositions pharmaceutiques les contenant
US5338745A (en) * 1990-08-10 1994-08-16 Mitsui Toatsu Chemicals, Incorporation Amide derivatives of dihydrocaffeic acid and their application to pharmaceuticals
WO2006024628A1 (fr) * 2004-08-30 2006-03-09 Janssen Pharmaceutica N.V. Derives de lactame tricyclique utilises en tant qu'inhibiteurs de 11-beta-hydroxysteroide deshydrogenase
US20060149070A1 (en) * 2005-01-05 2006-07-06 Rohde Jeffrey J Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme

Also Published As

Publication number Publication date
JP2016026165A (ja) 2016-02-12
JP2012524121A (ja) 2012-10-11
JP5848698B2 (ja) 2016-01-27
CN102459158A (zh) 2012-05-16
CN103772239A (zh) 2014-05-07
MX2011011082A (es) 2011-11-04
CN103772239B (zh) 2017-04-12
CN102459158B (zh) 2015-11-25
CA2757866A1 (fr) 2010-10-28
WO2010123838A3 (fr) 2011-03-03

Similar Documents

Publication Publication Date Title
JP5848698B2 (ja) 新規アミドおよびアミジン誘導体ならびにこれらの使用
JP5607021B2 (ja) １１−β−ヒドロキシステロイドデヒドロゲナーゼ１型酵素の阻害薬としてのアダマンチル誘導体
US8507493B2 (en) Amide and amidine derivatives and uses thereof
US7880001B2 (en) Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
KR101321728B1 (ko) １１-베타-하이드록시스테로이드 데하이드로게나아제 타입 １ 효소의 억제제로서의 아다만틸-아세트아미드 유도체
MXPA05006728A (es) Amidas sustituidas.
NZ555971A (en) Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US8372841B2 (en) Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US9133145B2 (en) Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
AU2011253958B2 (en) Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
AU2011202889B2 (en) Adamantyl-acetamide derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
AU2013206051B8 (en) Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080026472.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10767602

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2757866

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2012507294

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/011082

Country of ref document: MX

122 Ep: pct application non-entry in european phase

Ref document number: 10767602

Country of ref document: EP

Kind code of ref document: A2